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INTRODUCTION  
Cervical carcinoma develops through precursor lesions in the cervix. Treatment of the 
premalignant lesions of the cervix is important in secondary prevention of cervical carcinoma. 
However, most of the premalignant lesions of the cervix regress spontaneously. Today one 
cannot distinguish between lesions that will progress to invasive carcinoma from the vast 
majority of the premalignant lesions that will spontaneously regress.  
 
As prevention of cancer has high priority, women diagnosed with moderate to severe 
premalignant cervical lesions are generally recommended to be treated by cervical cone 
excision. The majority of the treated women are in their reproductive age. It is now known 
that cervical cone excision is associated with increased risk of preterm delivery in subsequent 
pregnancies. Since the premalignant lesion will regress in many women, specific prognostic 
markers of progression to cervical carcinoma are needed.  
 
Persistent infection with high-risk human papillomavirus (HPV) is the primary cause of 
cervical carcinoma. HPV infections are very common and the majority of HPV infections will 
spontaneously regress without clinically disease. To improve the identification of women at 
risk for developing cervical carcinoma, we need a better understanding of the natural course 
of the different HPV infections and biomarkers that can detect the premalignant lesions that 
will progress to invasive carcinoma. 
 
The objective of this thesis was to investigate  
I) the impact of cervical cone excision on the outcome of subsequent pregnancies,  
II) to estimate the number of preterm deliveries that may be prevented by an HPV16/18 
vaccination programme,  
III)  to compare HPV mRNA testing and HPV DNA testing for detection of cervical 
neoplasia,  
IV) to study the HPV genotype profile and presence of multiple infections according to 
severity of cervical neoplasia. 
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BACKGROUND 
 
CERVICAL ANATOMY 
The cervix (form Latin “neck”) is the name of the most inferior portion of the uterus, 
protruding into the upper vagina. The protruding part is referred to as the portio vaginalis or 
ectocervix. The opening of portio is called the external os. The passage between the external 
os and the uterine cavity is referred to as the endocervix which ends at the internal os which is 
the opening to the uterine cavity (Figure 1). The length and width of the cervix varies, but it is 
approximately three cm in length and between two and three cm in width in reproductive 
women.   
 
      
Figure 1. The human uterus. Adapted from www.clarian.org/ADAM/doc/graphics/images/en/19263.jpg  
 
 
 
The cervix is composed of a mixture of connective tissue, muscular and elastic tissue of 
which the connective tissue is the predominant component. The portio vaginalis is lined by 
multi-layered squamous epithelium while the endocervix is lined by columnar epithelium. At 
the portio vaginalis, the squamous epithelium of the portio meets the columnar epithelium of 
the endocervix in the squamocolumnar junction or transformation zone (Figure 2). Most 
neoplastic lesions develop from the squamous epithelium in the transformation zone.1 
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Figure 2. The transformation zone. Adapted from www.prn.org/images/uploads/Palefsky-fig3-680.gif   
 
 
The central function of cervix during pregnancy is to keep the foetus in utero. During 
pregnancy, the cervix must therefore remain unyielding and reasonably rigid. With the 
prelude to labour, the cervix must soften and yield. The cervical modifications during the first 
phase of labour involve mainly changes in the connective tissue. The results of these changes 
are cervical thinning, softening, and relaxation, which allow the cervix to initiate dilatation. 
The dilatation of the cervix will proceed until the cervix is fully dilated (about ten cm) and 
allow passage of the foetus. In preterm deliveries, these cervical modifications start 
premature. 
 
 
 
OCCURRENCE OF DISEASE  
Occurrence of cervical carcinoma  
Cervical carcinoma is the second most common cancer among women in the world. Almost 
500 000 women are diagnosed with invasive cervical carcinoma each year and 288 000 
women die of cervical carcinoma every year, of whom 80% in developing countries.2, 3 In 
Norway, as in many Western countries, the incidence and prevalence of cervical carcinoma 
decreased after implementation of cytological screening programmes. In 2008, 270 women 
were diagnosed with cervical carcinoma and in 2007, 84 women died of cervical carcinoma in 
Norway.4  
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Occurrence of pre-invasive cervical lesions  
About ten million women are diagnosed with high-grade cervical lesions (CIN2+) and about 
30 million women are diagnosed with low-grade cervical lesions every year world wide.2 In 
Norway, 5288 women were diagnosed with high-grade cervical lesions and 17031 were 
diagnosed with low-grade lesions by cytological examination of cervix in 2008.4 In Norway, 
about 80% of the women with histological verified high-grade cervical lesions (CIN2+) were 
in reproductive age (Table 1).  
 
 
Table 1.  Number of women with histological verified CIN2+ in Norway based on data from The Cancer 
Registry of Norway, 2007.  
 
Age  CIN2  CIN3   ACIS Total 
0-19  11  18  0  29 
20-24  71  191  5  267 
25-29  107  498 20 625 
30-34  82  566  29  677 
35-39   72  430 22 524 
40-44  57  334  15  406 
45-49  42  173  7  222 
50-54  31  87  5  123 
55-59  26  68  8  102 
60-64  11  34  2  47 
65-69  8  31  5  44 
70-74  4  18  3  25 
75+  2  17  3  22 
Total  524  2465  124 3113 
 
 
 
Identification of women at risk for cervical carcinoma 
Cervical cancer screening programmes were introduced in order to identify women at risk of 
developing cervical carcinoma for treatment of pre-cancerous lesions and thereby prevent 
cancer development. The International recommendations for cervical cancer screening 
suggest that screening should start before 35 years of age with no less than three-year 
interval.2, 5 The Norwegian Cervical Cancer Screening Programme started in 1995.4 All 
women between 25 and 70 years of age living in Norway are invited to participate, and 
cervical cytological sampling is performed in primary health care. In Norway, 429790 
cervical cytological examinations and 21735 histological examinations of cervical biopsies 
were performed in 2008.4  
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DIAGNOSIS OF CERVICAL NEOPLASIA 
 
Cervical neoplasia comprises premalignant and malignant lesions in 
the cervix and is diagnosed by colposcopy, cytological and 
histological examinations of specimens from the cervix. 
Cytology was developed by Papanicalaou in the 1930s. His method is 
referred to as the Pap smear and is still used in the cervical cancer 
screening programmes.6  
George N. Papanicolaou 
 
Cells from the ecto- and endocervix are collected for conventional light microscope 
examination. Histological examinations are based on colposcopically directed cervical 
biopsies from the transformation zone, endocervical curettage and cone specimens of the 
cervix. 
 
 
Cytological classification of cervical neoplasia 
Precancerous lesions in cytological samples are classified according to the Bethesda system.7 
The squamous lesions are classified as low-grade squamous intraepithelial lesions (LSIL) 
(Figure 3) and high-grade squamous intraepithelial lesions (HSIL). A precancerous lesion in 
the glandular cells is not graded but classified as adenocarcinoma in situ (ACIS). The 
Bethesda system also opens for doubt, using the terms atypical squamous cells- uncertain 
significance (ASC-US), atypical squamous cells- cannot exclude HSIL (ASC-H) and atypical 
glandular cells of uncertain significance (AGUS). The sensitivity of cytology testing for 
detection of cervical neoplasia varies between laboratories, ranging from 30 to 87%.8 The 
glandular lesions are more often missed by cytology than the squamous lesions. According to 
the Norwegian guidelines women diagnosed with HSIL, ACIS, ASC-H, and AGUS are 
referred to a gynaecologist for colposcopy, cervical biopsy and endocervical curettage.9 
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Figure 3. Pap smear showing a low-grade squamous intraepithelial lesion (LSIL). Adapted from Wikipedia, 
www.wikipedia.org/wiki/Papanicolaou_stain  
 
 
 
 
Histological classification of cervical neoplasia 
The squamous cervical lesions are now classified by the cervical intraepithelial neoplasia 
(CIN) terminology described by Richart in 1973.10 This system, which is based on the 
severity of atypia and the distribution of mitoses in the squamous epithelium, are graded into 
CIN1, 2 and 3 (Figure 4). CIN1 corresponds to mild dysplasia in the old WHO classification; 
CIN2 corresponds to moderate dysplasia and CIN3 to severe dysplasia and carcinoma in situ. 
Precancerous lesions in glandular cells are not graded and are classified as adenocarcinoma in 
situ (ACIS). When the basement membrane is breached by the neoplastic cells allowing for 
local spread and also distant metastasis, it is diagnosed as invasive cervical carcinoma. 
 
The majority of malignant tumours in the cervix are carcinomas which originate in the 
squamous or the glandular epithelium via premalignant lesions. The predominant histological 
type is squamous cell carcinoma (77%), and the adenocarcinomas comprise approximately 
15%.3,4 
 
In this thesis we focused on pre-invasive lesions of the cervix. 
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Normal             CIN1             CIN2 
 
     
CIN3              Invasive cervical carcinoma 
 
Figure 4. Histological classification of cervical neoplasia. With permission from A. K. Lie. 
 
 
 
 
THE NATURAL HISTORY OF CERVICAL NEOPLASIA 
Most cervical neoplastic lesions develop from the transformation zone of cervix where the tall 
columnar cells are constantly being transformed into flat squamous cells. This metaplastic 
change occurs in all women of reproductive age. When the process becomes abnormal, it may 
lead to the development of precancerous lesions of the squamous epithelium in the cervix. 
These lesions are characterised by abnormal maturation, high mitotic activity, nuclear 
enlargement and atypia and are called cervical intraepithelial neoplasia (CIN) (Figure 4). 
Neoplastic lesions in glandular cells develop from the columnar epithelium in endocervix. 
  
The risk of CIN progressing into invasive carcinoma of the cervix depends on the severity of 
the lesion (Figure 5). Ostor concluded that a proportion of 1%, 5% and > 12% for CIN1, 
CIN2 and CIN3 respectively, develop into cervical carcinoma (Table 2).11 His classical 
review is based on studies published between 1950 and 1990. The follow-up time in the 
included studies varied between 0.5 -10 years.   
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Table 2. Natural history of CIN.11 
 
 Regress Persist Progress  to CIN3 Progress to cervical 
carcinoma 
CIN1 57% 32% 11% 1% 
CIN2 43% 35% 22% 5% 
CIN3 32% <56% - >12% 
 
 
 
At the National Women’s Hospital, Auckland, New Zealand, treatment of CIN3 was withheld 
from a substantial number of women between 1965 and 1974 as part of an unethical clinical 
study.12 A judicial inquiry referred all women included in this study for independent clinical 
review in 1988, resulting in recorded follow-up of 1229 women, and this is the most recent 
publication on this subject.13 Among women with CIN3, the cumulative incidence of invasive 
cervical carcinoma was 31.3% (95% CI 22.7–42.3) 30 years after the diagnosis, while the 
incidence was 50.3% (37.3–64.9) among the women who had persistent CIN3 in at least 24 
months. 
 
 
 
CIN1
CIN2
CIN3
Squamous cell carcinoma
Normal squamous 
epithelium
12-31%
HPV
 
Figure 5. The risk of CIN progressing into cervical carcinoma. Adapted from The CIBA Collection of Medical 
llustrations. 
 
 
Cytological and histological examinations cannot reliably distinguish the women with high-
risk precursor lesions that will progress to invasive carcinoma from the vast majority of those 
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precursor lesions that will spontaneously regress. Since few premalignant lesions progress to 
invasive carcinoma, there is a need to find biomarkers to identify women at risk for such 
progression.  
 
 
 
THE CAUSES OF CERVICAL NEOPLASIA   
 
Harald zur Hausen received the Nobel Prize in Physiology and 
Medicine in 2008 for his pioneering work more than 30 years ago, 
concerning the role of human papillomavirus (HPV) in the 
development cervical carcinoma.14 Certain high-risk genotypes of 
HPV have now been established as etiologic agents for the 
development of high-grade cervical neoplasia and cervical 
carcinoma.15-18  
Harald zur Hausen 
 
Most women who get infected with HPV will, however, never develop high-grade cervical 
neoplasia. A number of cofactors are therefore likely to be involved in the carcinogenesis, or 
in some women protective factors are present. Several co-factors of progression to neoplasia 
in HPV infected women have been suggested: environmental or exogenous cofactors 
including hormonal contraceptives, tobacco smoking, diet and co-infections with other 
sexually transmitted agents or immunodeficiency viruses, and host co-factors including parity, 
genetic factors and host immune response.17, 19-30  
 
 
 
THE NATURAL HISTORY OF HUMAN PAPILLOMAVIRUSES (HPV) 
More than 100 different HPV genotypes have been identified, and at least twelve of these 
have been linked to the development of cervical neoplasia and therefore classified as high-risk 
genotypes.31  
 
Based upon epidemiological studies HPV viruses are classified as high-risk, probably high-
risk and low-risk types (Table 3).31  
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Table 3.  Classification of HPV genotypes according to their oncogenic potential.31  
 
 
 
 
 
 
 
The vast majority of HPV infections are asymptomatic and transient, especially in the young 
population, and more than 90% of incident infections will resolve within two years.32  
 
Low-risk genotypes, such as HPV6 and 11, are most likely to resolve, whereas high-risk 
genotypes such as HPV16 and 18 have slower rates of clearance.32 Some women resolve the 
infection quite rapidly, within months, and others take up to three years. The duration of 
persistence of high-risk HPV infection required for development of CIN3+ appears to vary 
between one to 10 years.32  
 
Papillomaviruses are non-enveloped, epitheliotropic, double-stranded DNA viruses, 
approximately 55nm in diameter. The genomic organisation of each papillomaviruses is 
remarkably similar and can be divided into three functional regions (Figure 6). The HPV 
genome contains a non-coding area, the late genes L1 and L2, which regulate viral coat 
proteins (with L1 being the major coat protein and also used to make virus-like particles used 
in the vaccines). The so-called early proteins (E1, E2, and E4-E7) are necessary for the 
replication of the viral DNA and for the assembly of newly produced virus particles within the 
infected cells. Both sets of genes are separated by a control region that does not code for 
proteins but contains cis-elements required for regulation of gene expression, replication of 
the genome, and its packaging into virus particles.  
 
Classification HPV genotypes 
High-risk 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 
Probably high-risk 26, 53, 66, 68, 73, 82, IS39 
Low-risk 6, 11, 40, 42, 54, 61, 70, 72, 81, CP 6108 
Not yet classified 55,  62, 64, 67, 69, 71, 83, 84 
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Figure 6. Genome organization of the papillomavirus. Adapted from Thomas Iftner, 
http://img.medscape.com/fullsize/migrated/585/223/erm585223.fig2.jpg 
 
 
Papillomaviruses are perfectly adapted to their natural host tissue, the differentiating epithelial 
cell, and exploit the cellular machinery for their own purpose.33 The natural history of HPV 
starts with infection of the epithelial basal cells. Access to the basal cells is thought to be due 
to a cut, tear or inflammation. The replication cycle within the epithelium can be divided into 
two parts. First, the viral genome is replicated to a copy number of about 100 and maintained 
for varying periods of time at this low copy number within the initially infected, but still 
replicating, competent cells. Second, once the basal cells are pushed to the suprabasal 
compartment, they lose their ability to divide and instead initiate the terminal differentiation 
program. As the cells travel up through the epithelium, different HPV proteins are expressed. 
In the upper layer of the epithelium, the late genes (L1 and L2) are expressed, and HPV DNA 
is packaged into the viral capsid. When cells are normally desquamated, infectious virion are 
released (Figure 7). 
 
Progression to high-grade intraepithelial lesions and invasive carcinomas is associated with a 
persistent high-risk HPV infection, integration of the HPV genome into the host 
chromosomes, loss or disruption of E2 and subsequent up regulation of E6 and E7 expression 
(Figure7).33-35 The critical molecules in the process of virus replication are the viral proteins 
E6 and E7, which are the oncogenes of the virus. Continuous expression of these genes is 
required for malignant transformation. E6 and E7 interact with a number of cellular proteins. 
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Among others, E6 and E7 mediate binding and degradation of the tumor suppressor genes 
TP53 and RB1, respectively, and interfere with cell-cycle regulation.33, 34 Constant activity of 
E6 and E7 leads to increasing genomic instability, accumulation of oncogene mutations, 
further loss of cell-growth control, and ultimately development of carcinoma.36 During the 
development of invasive carcinoma, the viral genomes integrate into the host chromosome, 
which results in a constant level of E6/E7 proteins via stabilisation of mRNA, probably by 
loss of negative regulation of transcription mediated by the viral E2 protein.35  
 
 
 
 
Figure 7. HPV mediated progression to carcinoma. Adapted from Woodman et al 2007.34 
 
 
 
There are differences between the E6/E7 proteins of high-risk and low-risk HPV genotypes, 
but these are often of a quantitative rather than qualitative nature.37 E6 and E7 proteins from 
low-risk types are less competent in interfering with p53 and pRb functions than E6/E7 
proteins from high-risk genotypes.38, 39 The expression of other viral proteins such as E4 result 
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in cytoskeleton changes resulting in perinuclear halos which is the hallmark of the koilocytic 
cell. Infections with low-risk genotypes are associated with benign proliferations, such as 
genital warts and low-grade intraepithelial lesions prone to regress. 
 
 
PRESENCE OF HPV   
HPV is the most common sexually transmitted infection among men and women, and it has 
been estimated that 70% of sexually active women will acquire an HPV infection at some 
point during their lifetime.40 Prevalence of HPV varies between geographic locations and age 
groups. The prevalence of HPV is high in young women. The prevalence declines in the 
middle-age groups and a second rise in prevalence is observed in women 35-54 years old 
(Figure 8).41   
 
 
Figure 8.  Age-specific HPV prevalence. Adapted from de Sanjose et al 2007.41  
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Prevalence of HPV in women with normal cervical cytology 
The most comprehensive available data on the HPV prevalence in women with normal 
cervical cytology derives from a large, global meta-analysis of the literature published in 2007 
compiled by the World Health Organisation.42 The study includes publications from 1999 up 
to early 2005 on 157 897 women, and only women with reported normal cytology were 
included. The results indicate that 10.4% (95% CI 10.2-10.7) of the women worldwide are 
positive for HPV DNA in cervix. HPV prevalence is higher in less developed regions (13.4%, 
95% CI: 13.1-13.7) than in more developed regions (8.4%, 955 CI: 8.3.-8.6). Similar results 
were observed in an International Agency for Research on Cancer (IARC) population-based 
survey conducted on 15613 women aged 15-74 years from eleven countries around the world. 
In all continents, HPV16 is the most common HPV genotype with an estimated point 
prevalence of 2.6% (95% CI: 2.5-2.8) worldwide.43 
 
 
HPV genotype distribution in women with pre-invasive cervical lesions 
Beyond HPV16, the relative importance of the different HPV genotypes for the development 
of cervical neoplasia remains insufficiently understood.15, 44-48 The distribution of HPV 
genotypes according to severity of cervical neoplasia can help us gain insight into the 
oncogenic potential of the different HPV genotypes. 
 
The HPV genotype distribution in women with pre-invasive cervical lesions has been 
described in several cross sectional studies.49, 50 Across all five continents, HPV16 has been 
reported to be the most common genotype in high-grade cervical intraepithelial neoplasia 
(CIN2+) with a contribution ranging from 33.3% in Oceania to 51.8% in Europe.49, 51-53 In an 
analysis of pooled data of more than 7000 women diagnosed with high-grade squamous 
intraepithelial lesions (HSIL) worldwide, the most common HPV genotypes worldwide 
were HPV16, 31, 58, 18, 33, 52, 35, 51, 56 and 45.49  
 
 
HPV genotype distribution in women with invasive carcinoma 
Also in cervical carcinomas, HPV16 is the most common HPV genotype detected in 53-57% 
of women with invasive cervical carcinoma (Figure 9).54, 55  The results from "Pooled analysis 
of the IARC cervical cancer series",2 an updated meta-analysis of 14500 women with invasive 
cervical carcinoma49 and the ICO survey54 are consistent in identification of HPV16 and 18 as 
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the two most prominent genotypes, followed by HPV45, 31 and 33 with small variability. 
HPV18 is more closely associated with cervical adenocarcinoma, which is more difficult to 
detect by cervical screening than squamous cell carcinoma.56  
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Figure 9. Worldwide prevalence of different HPV genotypes in invasive cervical carcinoma. Adapted from 
Clifford, 2006.55  
 
 
HPV16, 18, 33 and 45 have been detected more frequently in invasive cervical carcinomas 
compared to premalignant lesions.49, 57 But an increasing prevalence of HPV33, 39, 52 and 58, 
and a decreasing prevalence of HPV45 and HPV18 have also been reported.58     
 
The natural history and oncogenic potential of different HPV genotypes is not sufficiently 
understood. Only follow-up studies of a large number of women with incident HPV infection 
can give reliable estimates of genotype specific prognosis. Such studies are costly and time 
consuming. In cross sectional studies, the distribution of HPV genotypes according to severity 
of cervical intraepithelial neoplasia (CIN) can help us gain insight into the oncogenic potential 
of the different HPV genotypes. 
 
The magnitude of increased risk for one specific HPV genotype compared to a reference HPV 
genotype as well as the role of multiple HPV infections in the progression of cervical 
neoplasia to carcinoma remains uncertain.46, 47, 59 Such knowledge may be essential to identify 
women at high-risk of disease progression from CIN2 to invasive carcinoma. 
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In a cross-sectional study, we therefore wanted to study the association between different 
HPV genotypes and presence of multiple HPV infection according to the severity of cervical 
lesion.  
 
 
 
METHODS OF HPV DETECTION 
Since HPV cannot be cultured, HPV has to be diagnosed by DNA, RNA or proteins in the 
infected tissue.60 The most commonly used HPV tests are based on direct hybridization or 
DNA-based amplification techniques. 
 
 
DNA-based amplification techniques 
Polymerase chain reaction (PCR) is regarded as the most sensitive technique and allows 
testing on samples with less tissue or cells, poorer DNA quality and fewer viral copies. The 
PCR tests are based on consensus or type-specific assays. The most commonly used 
consensus PCR targets the highly conserved L1-region. After PCR, the amplicon can be used 
for genotyping with genotype specific probes. L1-based PCR tests can give false-negative 
results in screening since integration of the HPV genome into the human chromosomes may 
result in loss of the L1 region.  
 
Commercial HPV assays based on L1 or E1 PCR for high-risk HPV DNA detection and 
genotyping are now available from different companies: among others Amplicor and Linear 
Array (Roche Molecular Systems, CA, USA), INNO-LiPA (Innogenetics, Ghent, Belgium) 
PapilloCheck (Greiner Bio- One GmbH, Germany) and Multiplex HPV genotyping kit 
(Multimetrix GmbH, Heidelberg, Germany). Limited clinical validation exists only for the 
Amplicor test.61-64   
 
 
Direct hybridization 
 In situ hybridization by chromogenic or fluorescence techniques is based on the 
complementary pairing of a labelled probe to HPV antigens or nucleic acids (DNA or mRNA) 
within either paraffin embedded tissue biopsies or cervical smears. Hybrid Capture 2 (HC2; 
Digene Corporation, MD, USA) is a signal-amplified hybridization microplate-based assay, 
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and at present the only US FDA-approved HPV test. This is the most widely used and 
clinically validated assay on the market.65-67 Hybrid Capture 2 can detect13 high-risk 
genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68). Limitations of this test are 
lack of internal control for the amount of input of DNA and cross-reactivity with HPV types 
not included in the probe mix resulting in false-negative and false positive results.53, 68, 69 
Hybrid Capture 2 cannot identify specific HPV types, hence other techniques have to be used 
for genotyping.  
 
 
RNA-based amplification techniques 
HPV E6/E7 mRNA is easier to detect than the viral proteins E6 and E7. Detection of HPV 
E6/E7 mRNA can be performed by reverse-transcriptase (RT)-PCR or by nucleic acid 
sequence-based amplification (NASBA).70, 71 Presence of E6/E7 mRNA transcripts represent 
oncogene activity in cervical specimens (Figure 10).  
 
 
 
 
 
Figure 10.  HPV mRNA testing. Adapted from NorChip. 
 
 
A NASBA-based assay detecting E6/E7 transcripts from the five most common high-risk 
HPV types in cervical carcinoma (16, 18, 31, 33 and 45) is now commercially available (same 
product, marketed under different brand names: PreTect HPV Proofer, NorChip AS, 
Klokkarstua, Norway and NucliSENS EasyQ, BioMerieux SA, France). The advantage with 
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PreTect HPV-Proofer and NucliSENS EasyQ is that both HPV detection and genotyping are 
performed in the same reaction.  
 
Gen-Probe is currently developing the APTIMA HPV Assay, targeting E6/E7 mRNA from 14 
carcinogenic HPV genotypes; a prototype of this assay has been evaluated in one cross-
sectional study.72 Meta-analyses, randomized clinical trials and expert reviews reveal that 
HPV DNA testing for the identification of women at risk of cervical neoplasia is more 
sensitive but less specific than cytology, and the positive predictive value is low.66, 73, 75-78, 136  
 
Since only a minority of HPV infected women develop cervical neoplasia, identification of 
HPV infected women by HPV DNA testing could result in follow-up of women with a 
clinically insignificant infection, resulting in increased costs and patient anxiety.  
 
It has been suggested that the detection of viral gene expression rather than the presence of 
HPV DNA, may be a better indicator to identify women at risk of developing high-grade 
cervical dysplastic lesions and cervical cancer (CIN2+). Expression of E6 and E7 mRNA 
have been found to increase with lesion severity,53, 70, 72, 79 therefore the detection of E6/E7 
mRNA may be of higher prognostic value and may improve the specificity and positive 
predictive value compared with HPV DNA testing in screening.52, 53, 80-86 However, no 
population studies have reported the predictive values of mRNA testing for developing 
CIN2+ compared to cytology or HPV DNA testing.  
 
The marketing of the commercially available DNA and mRNA molecular based HPV tests 
has been offensive. There are, however, no population-based studies that compare the 
predictive values for detection of cervical neoplasia of these tests in screening. Comparisons 
between different HPV tests methods with regard to sensitivity and specificity for detection of 
HPV and also for the prediction of women whom will develop cervical neoplasia remains 
insufficiently studied. Few studies have compared HPV mRNA and HPV DNA testing with 
regard to detection of cervical neoplasia. 
 
Therefore we wanted to compare three different commercial available HPV assays with 
regard to the detection of HPV, and to compare the strength of the association between a 
positive test result and the severity of the cervical lesion between the HPV-test methods. 
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TREATMENT OF PRE-INVASIVE CERVICAL LESIONS  
Treatment of pre-invasive cervical lesions is an important measure in the secondary 
prevention of cervical carcinoma. Women with CIN2 or more severe lesions are generally 
recommended to be treated by cervical cone excision.9, 87-90 Basically, two treatment options 
exist: cervical cone excision or ablative treatment without excisional surgery. Cervical cone 
excision can be performed by cold knife, laser, or loop electrosurgical excision procedure 
(LEEP) (Fig.11). In contrast to ablative procedures such as electrocautery, laser or 
cryosurgery, cone excision gives a specimen for evaluation of radicality and final histological 
staging. No technique seems to be superior to another with regard to avoiding recurrent 
disease.88    
 
According to Norwegian guidelines, cold knife excision is not recommended, except when 
invasive disease is suspected.9 LEEP and laser cone excision are less invasive procedures than 
cold knife excision and are performed as out-patient treatment. Laser cone excision involves 
special training and is more costly than LEEP procedures.  
 
Cone excision is commonly performed in countries with a cervical cancer screening 
programme. In the European Union 163 000 cervical cone excisions are estimated to be 
performed yearly.2 In Norway about 3 000 cone excisions are performed yearly.4 
 
 
Figure 11. The principal of cervical cone excision. Adapted from 
http://www.nycosmetics.com/assets/8/Cone_biopsy.jpg 
 
 
 28 
Consequences of cervical cone excision for subsequent pregnancies 
Lund and Bjerkedal showed, as early as in 1986, that cold knife cone excision had an adverse 
effect on subsequent pregnancies, with a relative risk of perinatal mortality of 3.4 in deliveries 
occurring after cone excision compared to deliveries prior to such treatment in women who 
gave birth before as well as after cone excision. Compared to deliveries in women without 
any cone excision, they found a relative risk of perinatal mortality of 11.4.91 
 
Until recently, it has been argued that LEEP and laser cone excision, to a lesser extent than 
cold knife cone excision, influences subsequent pregnancy outcome. However, results have 
been uncertain, and the risks associated with LEEP and laser cone excision were not well 
known.92-97 We therefore wanted to estimate risks associated with LEEP and laser cone 
excision of perinatal death, preterm delivery, low birth weight and preterm premature rupture 
of membranes (pPROM). 
 
 
 
PRIMARY PREVENTION OF CERVICAL CANCER 
In the early 1990s work started on the development of prophylactic vaccines against specific 
HPV genotypes. The vaccines were created from the L1 major capsid proteins of virus-like 
particles of specific HPV genotypes. These particles are non-infectious and do not contain 
viral genetic material.  
 
Two prophylactic HPV vaccines are now commercially available. Gardacil is a quadrivalent 
vaccine which protects against HPV6, 11, 16 and 18 and is developed by Merck and C. Inc 
(West Point, Pennsylvania, USA).  Cervarix is a bivalent vaccine which protects against 
HPV16 and 18 and is developed by GlaxoSmithKline Biologicals (Rixensart, Belgium). Both 
vaccines are approved by the US Food and Drug Administration (FDA) and have been 
licensed in Europe.  
 
Studies on the effectiveness of these vaccines have been encouraging. Both vaccines have 
undergone double-blind, placebo-controlled phase III clinical trials in North America, Latin 
America, Europe and the Asia-pacific region. After three doses of either the quadrivalent or 
bivalent vaccine, almost 100% of women aged 15-26 had detectable antibodies to each HPV 
genotype, with levels being 10-104 times higher than those seen in natural infections98-100  
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For the quadrivalent vaccine, 12167 women aged 16-26 at enrolment were vaccinated with 
either the vaccine or placebo. The endpoints measured were CIN2/3, ACIS, cervical 
carcinoma and genital warts. In the 5305 vaccinated women who had no evidence of past or 
present infections with HPV16/18, and who received all vaccine doses, the vaccine efficacy 
was 98% (95% CI: 86-100) against CIN2+ related to HPV16/18 after a  mean follow up 
period of three years. If the women with less than perfect compliance also were included, the 
vaccine efficacy was 95% (95% CI: 85-99) for the same endpoints. The quadrivalent HPV 
vaccine has shown cross protections against non-vaccine HPV genotypes, most notable for 
HPV31.101, 102  
 
For the bivalent vaccine, 18644 women aged 15-25 at enrolment were vaccinated with either 
the vaccine or placebo. The endpoints measured were CIN2/3, ACIS and cervical carcinoma. 
In the final analysis of phase III trials of the bivalent vaccine, the vaccine efficacy against 
CIN2+ associated with HPV16/18 was 98.1% (95% CI: 88.4-100) in HPV negative women at 
baseline. Vaccine efficacy against CIN2+ irrespective of HPV genotype in lesions was 70.2% 
(95% CI: 54.7-80.9) in women who were HPV negative at baseline. Corresponding results for 
CIN3+ were 87.0% (95% CI 54.9-97.7) in HPV negative women at baseline.103  
 
 
HPV vaccination - an impact on preterm delivery? 
Based on the vaccine efficacy against CIN2+, a vaccination programme against HPV16/18 is 
likely to reduce the need for cervical cone excision. Since cone excision is likely to cause 
preterm delivery, an HPV16/18 vaccination programme may therefore also prevent some 
preterm deliveries. Numbers of preterm deliveries that may be prevented by an HPV 
vaccination programme has, to our knowledge, never been estimated. Therefore, we wanted to 
estimate a possible range of preterm deliveries per 100 000 pregnancies that may be prevented 
by an HPV16/18 vaccination programme. 
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AIMS OF THE STUDIES IN THIS THESIS 
 
I) To investigate the risks associated with cervical laser conisation or loop electrosurgical 
excision procedure of perinatal death, preterm delivery, low birth weight and preterm 
premature rupture of membranes (pPROM) (Paper I).  
 
II) Estimate the number of preterm deliveries per 100 000 pregnancies that may be prevented 
by an HPV16/18 vaccination programme (Paper II).   
 
III) To compare HPV mRNA testing and HPV DNA testing with regard to detection of HPV 
in women with and without cervical neoplasia. We also wanted to compare the association 
between positive test results by the different HPV assays used and the severity of the cervical 
lesion (Paper III). 
 
IV) To study HPV genotype distribution and the presence of multiple HPV infections in 
women with high-grade precancerous lesions. We also wanted to identify the HPV genotypes 
more prevalent in CIN3+ than in CIN2 and to estimate the odds ratios of CIN3+ for infections 
with different HPV genotypes and combinations  HPV infections (Paper IV).  
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MATERIALS AND METHODS 
 
PAPER I 
Study design and study samples 
The study “Pregnancy outcome after cervical cone excision: a case-control study” was a 
multi-centre study within a cohort of women who gave birth at nine different hospitals in the 
Southern part of Norway (Table 4). The study included 742 women who had been treated 
with loop electrosurgical excision procedure (LEEP) or cervical laser conisation (CLC) and 
742 women who had not been treated with cervical cone excision. Women were included 
from the following hospitals: Østfold Hospital Trust, Sørlandet Hospital Trust Arendal, 
Sørlandet Hospital Trust Kristiansand, Vestfold Hospital Trust, Telemark Hospital Trust, 
Bærum Hospital, Buskerud Hospital Trust, Ringerike Hospital and Rikshospitalet University 
Hospital.  
 
The study in Paper I was classified as a case-control study. This is, however, not the case. It 
was a retrospective cohort study. In case-control studies individuals are included in the study 
based on whether they do (cases) or do not (controls) have the condition in question. The 
groups with and without disease are compared with regard to prevalence of exposures. 
In cohort studies subjects are followed from a certain point of time, usually the exposure 
defining event, until the development of disease or censoring/end of the follow-up period.  
 
In our study, treatment by LEEP or CLC was the exposure. The exposed women were 
indentified through the participating hospital’s patient records, and followed through delivery. 
Also women who had not been treated with cervical cone excision were identified from the 
hospitals’ patient registries and followed through delivery. Pregnancy outcomes according to 
exposure were compared. Our study should therefore be classified as a retrospective cohort 
study, rather than a case-control study as stated in the paper. 
 
Identification of women treated with cervical cone excision 
We identified all women who had undergone either LEEP or CLC by using the participating 
hospital’s patient’s records during the period from January 1, 1990 through to December 31, 
1999. Women who were 40 years of age or younger at the time of conisation, were contacted 
with a postal letter with study information and a request for permission to collect information 
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about their obstetrical history from their medical records. Women, who consented to 
participate and delivered an offspring after 16 weeks of pregnancy at one of the participating 
hospitals subsequent to cone excision, were included in our study.  
 
Of the 742 included women treated with cervical cone excision, 419 women had given birth 
before conisation. The occurrence of the pregnancy outcomes; perinatal mortality, preterm 
delivery, birth weight and preterm premature rupture of membranes (pPROM) was compared 
before and after conisation in women who had undergone such treatment and also compared 
to women who had not undergone treatment.  
 
Identification of women not treated with cervical cone excision 
Women without cervical cone excision were identified from the respective participating 
hospital’s birth registries as the first woman who delivered, after the index women (the 
women treated with conisation) and whom had the same age (+/- 2 years), parity and 
plurality.  
 
 
Table 4. Study samples and study design of included papers. 
Study  Study samples Study design Enrolment to study  
Paper I 742 women who gave birth 
after cervical cone excision* 
742  women without cervical 
cone excision* 
Multi-centre, 
retrospective cohort 
study 
From January 1990 trough 
December 2003  
Paper II Literature from 1999-2008  
 
Estimations based on 
modeling  
 
Literature search in PubMed 
and MEDLINE from January 
1980 through September 2007 
Paper III 
 
643 women with CIN2+**  
736 with normal cytology  
Cross-sectional study From January 2005 through 
December 2006 
Paper IV 643 women with CIN2+**  Cross-sectional study From January 2005 through 
December 2006.   
 
*Women were recruited from the following hospitals: Østfold Hospital Trust, Sørlandet Hospital Trust Arendal, 
Sørlandet Hospital Trust Kristiansand, Vestfold Hospital Trust, Telemark Hospital Trust, Bærum Hospital, 
Buskerud Hospital Trust, Ringerike Hospital and Rikshospitalet University Hospital.  
**Women were recruited from the following hospitals: Østfold Hospital Trust, Akerhus University Hospital and 
Innlandet Hospital Trust.  
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Variables 
Dependent variables 
Our dependent variables were perinatal mortality, gestational duration, birth weight and 
preterm premature rupture of membranes (pPROM). Perinatal mortality was defined as 
number of deaths among all still-and live births after 22 weeks of gestation, including 
neonatal deaths during the first week after delivery.   
 
Estimations of gestational age were calculated from ultrasound due date (scan performed 
between 17 and 19 weeks) and used in the data analyses as both a continuous variable (days) 
and as the following categories: delivery before 37, 32 and 28 weeks (yes/no). Birth weight 
was used as a continuous variable in grams and as the following categories: birth weight less 
than 2500, 1500 and 1000 grams (yes/no). PPROM was defined as rupture of membranes 
before 37 completed weeks of gestation and before onset of labour.  
 
Independent variables 
Independent variables were treatment by cervical cone excision (yes/no). Cervical cone 
excision was done by either laser conisation or LEEP. Treatment by LEEP or CLC depended 
on the choice of operating procedure routinely used at the respective hospital. Also depth of 
the cone was used as the independent variable. The cone depth was measured in millimetres 
as the vertical depth of the cone after fixation.  
 
Potentially confounding variables 
Marital status, levels of education and smoking habits were included in the data analyses as 
confounding variables. Marital status was categorised as married/co-habitant or 
single/divorced/widow. Smoking habits was categorised as smokers or non-smokers during 
pregnancy. Level of education was categorised as <12 years or >12 years of education. 
 
 
Statistical analysis 
Differences in perinatal mortality, preterm delivery, birth weight and pPROM in women with 
and without cervical conisation were compared using chi-squared and Fisher exact tests. 
Differences in perinatal mortality, preterm delivery, birth weight and pPROM before and after 
conisation in the same woman were estimated by using McNemars test. Continuous data were 
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compared with t tests. To study the association of cervical conisation and preterm delivery 
also odds ratios were estimated with 95% confidence intervals in logistic regression analyses. 
Adjustment was made for potentially confounding factors; smoking during pregnancy, marital 
status and educational level. The relationship between depth of the cone excised and the risk 
of preterm delivery was estimated by Spearman product-moment correlation. Continuous data 
were given as mean ± standard deviation (SD). The statistical analyses were conducted using 
SPSS software, version 13.0. 
 
 
 
PAPER II 
Study design and study samples 
In the study “Vaccination against human papillomavirus-an impact on preterm delivery? 
Estimations based on literature review”, we made estimations on the number preterm 
deliveries that may be prevented by HPV16/18 vaccination based on a mathematical model.  
 
The number of prevented preterm deliveries depends on the number of preterm deliveries 
caused by cervical cone excision (extent of the health problem), and the proportion of this 
health problem that could be prevented by a vaccination programme. The number can be 
estimated as follows:  
 
The extent of the health problem was defined as: a (b-c);   
a = the proportion of pregnant women treated with cervical cone excision,  
(b-c) = the proportion of preterm deliveries attributable to cervical cone excision = the 
proportion of preterm deliveries in women treated with cone excision (b) minus the 
proportion of preterm deliveries in women not treated with cone excision (c).  
The preventable proportion was defined as; d  e 
d = the proportion of cervical cone excisions that can be prevented by vaccination, 
e = the proportion of childbearing women who have been vaccinated.  
 
The number of preterm deliveries prevented by a vaccination programme can thereby be 
estimated as the extent of the health problem; a (b-c) multiplied with the preventable 
proportion; d  e.  
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We obtained values on the proportion of preterm deliveries attributable to cervical cone 
excision from the scientific literature. To identify relevant studies, a search in PubMed and 
MEDLINE from January 1980 through September 2007 was performed using the search 
words: “pregnancy” and “loop electrosurgical excision procedure “ (“LEEP”, “LETZ”, 
“LLETZ”), “loopexcision”, “cervical cone excision”, “conization” or “conisation”. Reference 
lists in the identified publications were searched manually to identify additional relevant 
studies. Two meta-analyses and five population-based registry studies were included.104-110  
 
We obtained values on the preventable proportion of cervical cone excision in vaccinated 
women from the scientific literature.100, 101, 111-115 
 
 
Study factors used in the estimations 
The proportion of pregnant women treated with cone excision. In our model, we included 
three different assumptions of the proportion of women who had been treated with cone 
excision prior to delivery; one, two and four percent. (Nohr B, personal communication)107, 
116, 117 
 
The proportion of preterm deliveries attributable to cervical cone excision.  
A range of probable proportions were obtained from the scientific literature. Only studies 
estimating the risk of preterm deliveries associated with LEEP or CLC were considered. We 
ensured that the studies giving the highest and the lowest risks for preterm delivery after 
cervical cone excision with adequate power and design were included. 
 
The proportion of cervical cone excisions that can be prevented by HPV vaccination.  
This proportion was set to be 65%.100, 101, 111-113 
 
The proportion of pregnant women who are vaccinated. 
This proportion was set to be 90%.114, 115  
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PAPER III AND PAPER IV 
Study design and study samples 
The studies “Performance of human papillomavirus DNA and mRNA testing strategies for 
women with and without cervical neoplasia” and “HPV genotype distribution according to 
severity of cervical neoplasia” were cross-sectional studies (Table 4). 
 
Participants were identified through the Cervical Cancer Screening Programme of Norway.4 
Enrolment took place from January 1, 2005 through December 31, 2006. Included in the study 
III were 736 women with normal cervical cytology and 643 women with CIN2+. Included in 
the study IV were only the 643 women with CIN2+. 
 
Identification of women with normal cervical cytology 
We included 736 women, 30 years or older, who had been through a routine gynaecological 
examination including cytological sample from the cervix. The women were recruited from 
general practitioners and gynaecologists in private practices who sent Pap smear samples to 
be evaluated at the Department of Pathology at Akershus University Hospital. The included 
women had normal Pap smear cytology, normal cytological results from the preceding two 
years and no history of treatment for cervical neoplasia. To be included in the study women 
were cross-checked with The Cancer Registry of Norway to ensure no prior history of 
cervical neoplasia or abnormal cytology. The median age was 51 years (range 31-82 years). 
 
Identification of women with CIN2+ 
We included 643 women (no age criteria imposed) with histological confirmed CIN2+ 
recruited from a source population of 424,143 women in Health Region East, and who were 
diagnosed at one of the following hospitals: Østfold Hospital Trust, Akershus University 
Hospital and Innlandet Hospital Trust. Of all women with CIN2+ (n=655), twelve women 
were excluded since their HPV tests were not evaluable. The median age was 35 years (range 
17-76 years). 
 
 
Cytological samples  
Cervical specimens for cytological examinations were collected from the ecto-and endocervix 
with Cytobrush Plus (Medscan Medical AB, Sweden). CellPath CytoFixx (Mochdre 
Enterprise, Newton UK) was used to prepare slides for cytological analysis. Cytological 
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diagnoses were defined according to the Bethesda nomenclature system.7 Normal cytology 
was defined as normal Pap smear cytology at inclusion time, normal cytological results from 
the preceding two years and no previous history of treatment for cervical neoplasia. 
 
 
Cervical biopsies and cones  
Cervical neoplasia was diagnosed with histological analyses of colposcopically directed 
biopsies and of cone specimens, according to the WHO classification of cervical neoplasia.118 
Most biopsies and cone specimens were primarily evaluated by light microscopy by one 
experienced pathologist (Lie, AK). If not, the specimens were re-evaluated by Lie, and at 
disagreement, Lie’s diagnoses were included in the study. The diagnosis was based on the 
most severe lesion seen in the biopsy or the cone specimen. Histology revealed CIN2 in 
21.0% of the women (135/643), CIN3 in 73.7% (474/643) and adenocarcinoma in situ (ACIS) 
in 3.3% (21/643). Invasive carcinoma was diagnosed in 2.0% (13/643) of the women. CIN2+ 
included CIN2, CIN3, ACIS and invasive carcinoma. In paper IV, we calculated risk of 
CIN3+ versus CIN2. CIN3+ included CIN3, ACIS (either isolated or together with CIN2/3) 
and invasive carcinoma. 
 
 
Detection of HPV 
 
Collection of specimens for HPV testing 
HPV testing was performed on cell suspension from cervix. For the normal cytological group 
a conventional Pap smear was taken first and the brush was transferred to a PreServ Cyt vial 
(Cytyc Corporation, USA) for HPV testing. For the women with CIN2+, specimens from the 
cervix were obtained with Cytobrush Plus collected at the time of conisation or at the time of 
biopsy taken within two months before conisation, and the brush was transferred directly to 
the PreServ Cyt medium. Cells were stored in PreServ Cyt medium for up to 21 days at room 
temperature or at 4C before HPV testing. 
 
HPV DNA testing and genotyping 
The presence of HPV DNA was detected by Amplicor and Linear Array. The Amplicor HPV 
test (Roche Diagnostics, Switzerland) detects the following HPV DNA genotypes 16, 18, 31, 
33, 35, 39, 45, 51, 52, 56, 58, 59 and 68. The Amplicor test does not include genotyping, and 
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a positive result of the test was interpreted as presence of one or more of the above genotypes. 
HPV DNA genotyping was performed with the Linear Array HPV assay (Roche Diagnostics, 
Switzerland) in women with normal cytology and positive HPV test and in all women with 
histologically confirmed CIN2+. This assay detects 37 different genotypes (Table 3). This 
was done retrospectively using the same extracts used for the Amplicor HPV test and PreTect 
HPV-Proofer test. The analyses were performed according to the manufacturer’s 
recommendation. 
 
HPV mRNA testing 
The presence of E6/E7 mRNA was detected by PreTect HPV-Proofer (Norchip, Norway) 
which detects E6/E7 full-length mRNA transcripts from HPV 16, 18, 31, 33 or 45. Samples 
that were HPV mRNA negative, internal control negative or internal control indeterminate 
(signal between 1.4-1.7), as well as samples that were HPV indeterminate were re-extracted 
and reanalysed as recommended by the manufacturer (Norchip, PreTect HPV-Proofer user 
guide version 1105 720001 and earlier). Samples that tested indeterminate twice were 
considered negative if the internal control was positive. 
 
Presence of HPV genotypes, Paper III  
Presence of HPV was defined as: HPV DNA detected with Amplicor (yes/no), presence of 
HPV DNA detected with Linear Array (yes/no) and presence of E6/E7 mRNA detected with 
PreTect HPV-Proofer (yes/no). In addition, the presence of HPV16, 18, 31 and 33 as detected 
by both PreTect HPV-Proofer and Linear Array were presented. 
 
Presence of HPV genotypes, Paper IV  
HPV DNA genotyping was performed with the Linear Array HPV assay. HPV genotypes 
were classified as high-risk, probably high-risk, low-risk and not yet classified (Table 3). 
We studied the presence of each high-risk HPV genotype separately. In addition, in a 
regression analyses, presence of HPV genotypes were categorized as follows: single infection 
with HPV16, 18, 31 or 33, co-infections with HPV16+31, HPV16+33, HPV16+18, HPV16 + 
any other HPV genotype, HPV33 + any other HPV genotype and HPV co-infections not 
including HPV16, 18, 31 or 33. Single HPV infection (except infection with HPV16, 18, 31 
or 33) was used as the reference category. Presence of multiple HPV infections were 
categorised as 1 genotype, 2-4 genotypes and >4 genotypes.  
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Statistical analysis 
In Paper III, statistical analyses were performed using 2x2 contingency tables with two-sided 
p-values calculated with Pearson’s Chi-square test. Fisher’s exact test and McNemar’s test 
were used for comparison of paired proportions. P-values <0.05 were considered statistically 
significant. Cohen's kappa statistics were used as indicators of concor	

indicate poor agreement, 0.21-0.40 fair agreement, 0.41-0.60 moderate agreement, 0.61-0.80 
substantial agreement and >0.80 indicate nearly perfect agreement. Kappa values were 
calculated for agreement between assays on detection of HPV16, 18, 31, 33 or 45.  
 
In paper IV, the prevalence of one specific HPV genotype in CIN3+ versus CIN2 was 
presented and compared by applying the Pearson’s chi-square test. The associations of HPV 
genotypes with CIN3+ were estimated as crude and adjusted odds ratios with 95% confidence 
intervals by applying logistic regression analyses. Age was included as a potentially 
confounding variable and coded as  The statistical analyses were 
performed by applying SPSS software, version 16.0. 
 
 
 
ETHICAL ASPECTS 
Prior to start of study I, written informed consent was obtained from all women to collect 
relevant information from the medical records in the respective hospitals. Data regarding the 
control group was extracted anonymously from birth registries based on matching properties, 
and written consents were not collected for the controls. The Regional Committee for Ethics 
in Medical Research, Region South, Norway (S-01151) approved the study on beforehand. 
 
Prior to start of study III and IV, written informed consent was obtained from all study 
participants. The Regional Committee for Ethics in Medical Research, Region East, Norway 
(676-04239), the Norwegian Health Directorate (05/163) and the Norwegian Data 
Inspectorate (07/00975-2/SVE) approved the study on beforehand.  
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SYNOPSIS OF INCLUDED PAPERS 
 
Paper I 
Objective. To investigate the effect of loop electrosurgical excision procedure (LEEP) or 
cervical laser conisation (CLC) on the outcome of subsequent pregnancies.  
 
Methods. Multi-centre, retrospective cohort study which included a cohort of 742 women 
whom, after treatment by LEEP or CLC, gave birth or suffered second trimester miscarriage.  
Control women (n=742) were extracted from the respective hospital birth registries and 
matched by age and parity. Outcome measures were perinatal mortality, length of gestation, 
birth weight and preterm premature rupture of membranes (pPROM).  
 
Results. There was no significant difference in perinatal mortality among women having 
undergone LEEP or CLC compared to the control group, 6/742 versus 2/742: OR= 3.1 (95% 
CI 0.6-15.2). Pregnancies after conisation were shorter than among the control group. The 
mean length of gestation was 270.6±25.5 days in the first pregnancy after conisation, 
compared to 279.7 ±12.7 days in the control group; t =8.5, p<0.001. Excluding second 
trimester miscarriages, odds ratio for giving birth before week 37, 32 and 28 after conisation 
compared to the control group were 3.4 (95% CI 2.3 – 5.1), 4.6 (95% CI 1.7-12.5) and 12.4 
(95% CI 1.6-96.1) respectively, after adjusting for smoking habits during pregnancy, marital 
status and educational level. Adjusted odds ratio of birth weight <2500g, <1500g, <1000g 
after conisation compared to the control group were 3.9 (95% CI 2.4-6.3), 4.4 (95% CI 1.5-
13.6) and 10.4 (95% CI 1.3-82.2) respectively. The adjusted odds ratio for pPROM was 10.5 
(95% CI 3.7-29.5). 419 of the women had given birth before conisation as well as after 
conisation. The duration of gestation was shorter in the first pregnancy after conisation 
compared to the last pregnancy prior to conisation. The mean length of gestation was 271.0 
±25.0 days in the first pregnancy after conisation compared to 277.6 ±16.3 days before 
conisation, t=5.0; p<0.001. Odds ratio for giving birth before week 37 and 32 after conisation 
compared to prior to conisation were 2.6 (95% CI 1.4-4.5) and 4.5 (95% CI 1.0-20.1) 
respectively. There was an inverse correlation with deeper cone excisions associated with 
shorter pregnancy duration: r = -0.12, n=599, p=0.01, corresponding to a 7% increased risk of 
preterm delivery for each millimetre excised.   
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Conclusion. Treatment by LEEP and CLC increases the risk of preterm delivery, low birth 
weight and pPROM in subsequent pregnancies.  
 
 
Paper II 
Objective. Cervical cone excision increases the risk of preterm deliveries. Vaccination against 
human papillomavirus 16/18 (HPV16/18) will probably prevent the development of high-
grade cervical intraepithelial neoplasia and thereby reduce the need for cervical cone 
excisions. An HPV16/18 vaccination programme may therefore also prevent some preterm 
deliveries. The aim of this study was to illustrate how different parameters influence the 
number of preterm deliveries that may be prevented by an HPV16/18 vaccination programme.  
In a model we included different values of these parameters and estimated a range of possible 
preventable preterm deliveries.  
 
Methods. We identified the parameters influencing the effect of an HPV16/18 vaccination 
programme on preterm deliveries, and estimated a possible range of preventable deliveries 
before the 37th week of pregnancy. The number of preterm deliveries prevented by HPV16/18 
vaccination programme will depend on the number of preterm deliveries related to cervical 
cone excision (extent of the health problem), and the proportion of this health problem that 
could be prevented by a vaccination programme. We obtained values of the parameters used 
in the estimations from the scientific literature.  
 
Results. If 2% of childbearing women are treated with cervical cone excision, between 60 and 
220 preterm deliveries/100 000 births may be related to such treatment. Close to 60% 
(between 35 and 128 preterm deliveries) could be prevented by an HPV16/18 vaccination 
programme, if the programme coverage was 90%. If 4% of women are treated with cone 
excision, between 70 and 257 preterm deliveries/100 000 births could be prevented. 
 
Conclusion. HPV16/18 vaccination programmes may reduce the number of preterm 
deliveries through reducing the need for cone excision.   
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Paper III 
Objective. To compare HPV mRNA testing and HPV DNA testing with regards of detecting 
HPV in women with and without cervical neoplasia. We also wanted to compare the 
association between positive test results by the different HPV assays used and the severity of 
the cervical lesion.  
 
Methods. We included 643 women with high-grade cervical neoplasia (135 cases of CIN2, 
495 cases of CIN3/ACIS and invasive carcinoma in 13 cases) and 736 women with normal 
cytology. HPV was detected using the Amplicor and PreTect HPV-Proofer assays. In 
addition, genotyping was performed with Linear Array in women with normal cytology and a 
positive HPV test and in all women with histological confirmed CIN2+.  
 
Results. In women with normal cytology; 8.3% (61/736) were Amplicor positive and 3.3% 
(24/736) were PreTect HPV-Proofer positive (p<0.001). Concordant results between 
Amplicor and PreTect HPV-Proofer were present in 90.3% (665/736). In women with CIN2+ 
lesions 96.4% (620/643) were positive by Amplicor, 98.4% (633/643) by Linear Array and 
64.1% (412/643) by PreTect HPV-Proofer. Concordant results for the three HPV assays were 
present in 63.8%. The genotype profile detected by Linear Array and PreTect HPV-Proofer 
showed substantial agreement for HPV16, 18, 33 and 45. HPV types 16 and/or 18 were 
detected in 58.8% (378/643) of the women with high-grade neoplasia. Detection of E6/E7 
mRNA by PreTect HPV-Proofer increased with severity of the cervical lesion. Detection of 
HPV DNA, however, was not associated with histology grade. 
 
Conclusion. The detection of HPV varied according to the assay used, and the concordance 
between the tests were poor. Our results indicate that mRNA testing may be a biomarker for 
progression of cervical neoplasia, but the optimal genotype mix remains to be determined. 
 
 
Paper IV 
Objective. To analyse the HPV genotype profile and the presence of multiple HPV infections 
according to severity of cervical neoplasia. 
 
Methods. From a population of 424,143 women in Norway, we included all women (n=643) 
with histologically confirmed cervical intraepithelial neoplasia grade 2 or higher (CIN2+) and 
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evaluable HPV test during 2005 and 2006. Histology revealed CIN2 in 135 women, 
CIN3/ACIS in 495, and invasive carcinoma in 13 women. HPV genotyping was performed on 
cell suspensions from cervix by linear array which differentiates 37 HPV genotypes.  
 
Results. HPV was detected in 98.4% (633/643) of the women, of whom 52.5% (338/643) 
were infected with more than one HPV genotype. HPV16was most common, being detected 
in 51.2% (329/643) of all cases, followed by HPV31, 33, 52, 18, and 51. Overall, HPV16 or 
18 were detected in 58.0% (373/643), with 34.7% (223/643) without concurrence of other 
high-risk genotypes. HPV16 and HPV33 as single infections were more common in women 
with CIN3+ as compared to CIN2 (age-adjusted odds ratio=5.93, 95% CI=2.73–12.87, and 
age-adjusted odds ratio=4.53, 95% CI=1.42–14.46, respectively). Concurrent infections with 
other HPV genotypes did not significantly alter the associations to CIN3+ for HPV16 or 
HPV33. A single HPV infection, other than HPV16, 18, 31, or 33, was used as the reference. 
HPV18 or multiple HPV infections not including HPV16 or HPV33 were not associated with 
the severity of cervical neoplasia. 
 
Conclusion. HPV16 and HPV33 appear to have a higher oncogenic potential than other HPV 
genotypes. 
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DISCUSSIONS 
 
PAPER I  
In Paper I, we estimated risks associated with LEEP and CLC on perinatal death, preterm 
deliveries, low birth weight and preterm premature rupture of membranes (pPROM).  
 
In our study, exposed women were matched with non-exposed women by age (+/- 2 years), 
parity, plurality and time of delivery. Matching was done in order to increase the power of the 
study by reducing the number of potential confounding variables. The matching variables 
could therefore not be investigated as possible risk factors for perinatal death, preterm 
delivery, low birth weight and pPROM. Logistic regression analyses were used to adjust for 
other confounding variables such as smoking during pregnancy, marital status and educational 
level. There may however have been other potential confounding factors, such as infections, 
that we have not adjusted for in our analyses.   
119-121  
 
Women with and without cone excision were identified through different patient records. 
Women treated with cone excision were identified through patient records of patients whom 
had undergone surgery and followed to delivery through their medical records. Women 
without cervical cone excision were identified through birth records at the maternity wards. 
Although it is common for women in second trimester to deliver at the maternity ward, some 
women may, however, have delivered in other departments. Hence, they may not have been 
registered in the birth records at the maternity ward and therefore not included in our study. 
Therefore, an underestimate of second trimester abortions may have occurred in the non-
exposed group in our study. In our study, 0.1% of the non-exposed women delivered between 
16 and 28 weeks of gestation. In a Norwegian population based study by Albrechtsen et al, 
0.4% of the women not treated by cervical cone excision delivered between 24-27 weeks of 
gestation.122 This difference suggests that an underestimation of second trimester abortions in 
the non-exposed women may have occurred in our study.  
 
Our results showed an increased risk of low birth weight after cervical cone excision. Low 
birth weight is associated with preterm birth. In our analyses, differences in gestational age in 
offspring born by women with and without cervical conisation could explain most of the 
 45 
differences in birth weight between the groups (data not shown). Therefore, our results with 
regard to low birth weight should be interpreted as a consequence of preterm delivery.  
 
We had limited statistical power to study differences in perinatal mortality between the 
women with and without cervical cone excision. Also, our estimated risk for delivery before 
28 weeks of gestation associated with cervical cone excision is uncertain.  
 
Studies published before 2002 on the risk for preterm delivery associated with LEEP or CLC 
were contradictory. Resents studies, however, are in agreement with our results, and an 
increased risk of preterm delivery after treatment by LEEP and CLC has been found. 104, 106-
109, 122-124 Our results and later publications have shown that the relative risk of preterm 
delivery attributed to cervical cone excision increases with decreasing gestational age.107, 122, 
123 The risk of preterm delivery was most pronounced in the early gestational age groups in 
which the clinical significance is the highest. 
 
Our results showed an association between cone depth and increased risk of preterm delivery. 
This is in agreement with other studies.108, 125-127 The proportion of the total cervical volume 
or endocervical canal removed may be more determinant of risk, than the actual depth of 
excision. In cold knife cone excisions, more cervical tissue is excised than in loop excisions. 
However, in loop excisions the cones may vary from superficial and low volume cones to 
deep and large volume cones. Most cervical cone excisions in young women with fully visible 
transformation zones need to be only 1 cm deep, and this should protect against serious 
obstetric outcomes.123 Caution should be exercised when treating fertile women who may 
wish to become pregnant in the future. Also, ablative treatments may be considered if the 
transformation zone is fully visible.110, 128-131 
 
Several mechanisms have been proposed to explain the increased risk of preterm delivery 
after cervical cone excision.  Removal of part of the cervix might compromise its functions, 
leading to lack of mechanical support in the cervix in future pregnancies. A reasonable 
hypothesis would be that the degree of obstetric morbidity noted might be related to the 
amount of the cervical tissue removed. As discussed above, several investigators have 
described a positive association between depth of excision and risk of adverse obstetric 
events. Others suggested that pathophysiological mechanisms might also be mediated by the 
different composition of the quality of collagen in the regenerated cervix or other 
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immunological factors, such as impairment of antimicrobial defence mechanisms after 
removal of cervical glands and thereby alteration of cervicovaginal bacterial flora. 
 
 
PAPER II 
In Paper II we made estimations on the number preterm deliveries that may be prevented by 
HPV16/18 vaccination based on a model. Our model was very simple and more advanced 
modelling could have been applied. Such model could have included a range of possible 
values of the parameters included and robustness of the model could have been tested. We 
had, however, no competence to use or define such advanced modelling tools. Our, model 
has, however the advantage of being easy to understand, easy to use, and also errors are easy 
to detect.    
 
The values of the parameters that we used to calculate the numbers of preventable preterm 
deliveries by an HPV vaccination programme are uncertain. However, the values in the model 
may be changed according to updated and better knowledge.  
 
The proportion of pregnant women treated with cone excision  
In most countries, the proportion of women treated with cone excision prior to delivery is not 
known. We included three different assumptions one, two and four percent. In a recent 
Norwegian study on all deliveries from 1967 to 2003, 2.6% of the women gave birth after 
cervical cone excision.122 
  
Our assumptions were based on results from a Danish and a Finish study where respectively 
2.3 - 3.04% and 0.8 % of the women had been treated with cervical cone excision prior to 
delivery (Nohr B, personal communication).107, 108, 116, 117 The differences in the proportion of 
pregnant women treated with prior cervical cone excision may represent country-specific 
differences or changes in clinical practice over time. In Finland the public cervical screening 
programme includes women !#$#
cone excision may therefore be higher in countries with women screened at younger age. The 
proportion of pregnant women treated with cone excision may be increasing in many 
developed countries since both the incidence of HPV infection132 and the mean age at delivery 
are increasing.122, 133  
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The proportion of preterm deliveries attributable to cervical cone excision 
We used point estimates from seven studies in our model. It may have been better to use a 
plausible range of values, and not simply show the point estimate for each included study. Of 
the included studies in our model, the study by Jacobsson107 has a sample size about 30 times 
larger than the remaining studies combined. Based on this, we may also have used only the 
Jacobsson study in our model, and used the confidence intervals from that study as a plausible 
range for the proportion of preterm deliveries attributable to cervical cone excision. However, 
this would not change our estimates significantly. 
 
The proportion of all cervical cone excisions that can be prevented by vaccination 
The effect of HPV16/18 vaccination on CIN2+, regardless of the causal HPV genotype, 
remains uncertain. We assumed a 65% vaccine effect on CIN2+, based on the reported 
distribution of HPV16/18 in CIN2+ lesions113 and the estimated 100% vaccine effect against 
these HPV genotypes and some additional cross-protection against other oncogenic 
HPVgenotypes.100, 101, 111, 112 These assumptions may be too optimistic. The Future I and II 
Study Group estimated a 27% (CI 95%; 4-44%) overall reduction of CIN2+ in an intention-
to-treat analysis.101 Not all women in the vaccine group received the three doses and some 
women may have been infected with HPV genotypes other than HPV16/18. If we assume a 
27% HPV16/18 vaccine effect on CIN2+ and 80% coverage of the vaccination programme, 
the range of prevented preterm deliveries will be between 7 and 95 per 100 000 births. 
However, in the final analysis of phase III trials of the bivalent vaccine published in 2009, the 
vaccine efficacy against CIN2+ irrespective of HPV DNA in lesions was 70.2% (95% CI: 
54.7-80.9) in women who were HPV negative at baseline.103   
 
The proportion of pregnant women who are vaccinated 
In our estimations we assumed 90% vaccination coverage, as is common in public childhood 
vaccination programmes in developed countries. However, vaccination coverage of the three 
recommended HPV vaccine doses in 12 year olds girls may be lower; hence our results of the 
number of preventable preterm deliveries may be overestimated. The last annual HPV vaccine 
coverage in United Kingdom for 12-13 years old girls was 88.6% for the first dose, 86.6% for 
the second dose and 80.9% for all three doses. (Morkved JH, Samofi Pasteur MSD, personal 
communication) The quadrivalent vaccine has been implemented in the National Vaccine 
Programme in Norway for 12 years old girls from the autumn of 2009.  By March 17th 2010, 
the overall vaccine coverage in Norway was 57%. However, vaccination against HPV has 
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been delayed in many municipalities in Norway due to vaccination of the pandemic influenza 
A (H1N1), and in ten percent of the municipalities in Norway, the vaccination against HPV 
have not yet started. It is therefore too early to draw conclusions about the vaccine coverage 
in Norway.115  
 
The surgical procedure may influence the risk of preterm delivery. In our model we included 
risk estimates after laser or loop electrosurgical excision only. The negative impact of cone 
excision may, however, be most prominent after cold knife excision.91, 123 If cold knife 
excisions are performed in childbearing women on a large scale, the number of preterm 
deliveries related to cone excision would have been underestimated in our study and 
consequently more preterm deliveries may be prevented by a vaccination programme.    
 
Up to 10% of all deliveries in developed countries are preterm.134 Only a fraction of all 
preterm deliveries can be attributed to cervical cone excision. In the study by Albrechtsen et 
al, the proportions of preterm delivery attributable to cervical cone excision before 37, 33 and 
28 weeks of gestation were 1.2%, 1.7% and 2.0% respectively.122 However, preterm delivery 
may cause serious disability for the child. Each prevented preterm delivery may therefore 
save the child and the family from suffering.  
 
To illustrate the potential effect of the HPV16/18 vaccination programme, a 70% reduction of 
cervical cancer incidence in Norway, will be from 9.5 to 2.9 cases per 100 000 women.4 As 
compared to the number of preventable cases of cervical cancer  through a vaccination 
programme, the number of preventable preterm deliveries may be considerable. When 
estimating healthy years of life gained by an HPV16/18 vaccination programme, the effect 
through reducing preterm delivery should also be considered. 
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PAPER III 
In Paper III we compared HPV mRNA testing and HPV DNA testing with regard to detection 
of HPV in women with and without cervical neoplasia. We also compared the association of 
positive test results with severity of cervical lesion according to the HPV test used. 
 
The prevalence of HPV varied according to the assay used, and the concordance between the 
tests was low. There are several explanations for the differences in test results. The different 
assays are not uniform with regards to the number of HPV genotypes the tests are addressed 
to detect and the tests differ in detection of HPV mRNA and DNA. 
  
PreTect HPV-Proofer was the HPV mRNA test we used, and it detects transcripts and 
oncogene activity from 5 out of the 13 HPV genotypes included in the Amplicor test (DNA 
test used). The Linear Array test, which was the other HPV DNA test we used, detects 37 
different genotypes. This may to some extent explain the differences in HPV prevalence 
estimated with these different HPV test methods. 
 
PreTect HPV-Proofer is based on nucleic acid sequence-based amplification (NASBA) 
whereas Amplicor and Linear Array are based on PCR that target the L1 region in the HPV 
genome.  L1- based PCR tests can give false negative results since integration of the HPV 
genome into the human chromosomes may result in loss of the L1 region. PreTect HPV-
Proofer tested positive in 2.3% of the Amplicor negative cases. This could be caused by false 
negative DNA tests due to break point in the L1 region during HPV integration, or false 
positive mRNA test. 
 
The agreement between Linear Array and PreTect HPV-Proofer in detection of the five 
genotypes included in both test was substantial for HPV16, 18, 33 and 45, and poor to 
moderate for HPV31. HPV mRNA-negative test results in HPV DNA-positive samples may 
be interpreted as HPV infections without active viral transcription or it may be that 
transcriptional activity occurs but at levels insufficient for PreTect HPV-Proofer detection. 
 
In women above the age of 30 with normal cytology, 3.3% tested positive with PreTect HPV-
Proofer and high-risk HPV DNA was detected in 8.3% with Amplicor. These prevalence’s are 
in agreement with another Norwegian study including 4000 women above the age of 30 with 
normal cytology, in this study PreTect HPV-Proofer tested positive in 2.4% of the women and 
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high-risk HPV DNA was detected in 9.3% of the women.135 In a study from South Carolina, 
USA in 2007 where the APTIMA HPV assay (detecting E6/E7 mRNA for 14 high-risk HPV 
types) was used, 8.0% of the women with normal cytology tested positive.72 It could be 
argued therefore that the smaller HPV genotype range of the PreTect HPV-Proofer explains 
lower prevalence. 
 
In our study 96.4% of women with CIN2+ tested positive with Amplicor which is in 
accordance with the large POBASCAM and ARTISTIC trials where HPV DNA testing was 
performed with PCR or Hybrid Capture 2.77, 78   
 
The number of high-risk HPV genotypes that should be included in an HPV test in order to 
achieve sufficient sensitivity and specificity  for development of cervical neoplasia remains to 
be documented. The natural history of the different HPV genotypes is not yet known. There 
will have to be a compromise between including low prevalent or less oncogenic HPV 
genotypes to maximise sensitivity or to include high prevalent HPV genotypes with high 
oncogenic potentials to increase the specificity. HPV tests detecting different panels of HPV 
genotypes may also be necessary to use in different parts of the world, since the prevalence of 
HPV genotypes is dependent on the geographic region. Moreover, as HPV vaccination 
embeds and the HPV prevalence of vaccine types may change, there will be a requirement to 
re-consider/recalibrate HPV assays in line with the shifting dynamics of HPV genotype 
specific prevalence and associated disease. 
 
A prognostic test for identification of the women who will develop cervical carcinoma and 
not only pre-cancerous lesions is warranted. With such test, numerous of unnecessary 
treatments with cervical cone excision could be prevented. An increased understanding of the 
oncogenic potentials of the different HPV genotypes and also increased understanding of 
expressions of oncogenic transformations may in the future enable development of prognostic 
tests with high specificity in detection of women with true risk of cancer development.    
 
Population based, randomized, clinical trials have shown that HPV DNA testing is more 
sensitive than cytology for detection of CIN2+.66, 75, 76, 136 The type-specific persistence of 
oncogenic HPV is considered to be the true precursor of neoplastic progression,137 whereas 
the expression of the E6/E7 oncogenes is necessary for the malignant transformation and 
maintenance of the neoplastic state.35 Therefore, the detection of the E6/E7 mRNA of the 
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respective HPV genotypes may serve as a better prognostic test than mere DNA detection for 
the development of high-grade cervical lesion.53, 135  
 
In our study, detection of E6/E7 mRNA by PreTect HPV-Proofer increased by severity of the 
cervical lesion, where as detection of HPV DNA was not associated with histology grade. 
This is in agreement with other studies.84, 135, 138 Detection of HPV oncogene activity, through 
the detection of mRNA transcripts may therefore be a better indicator of HPV infection 
associated with increased risk of progression to neoplasia, than detection of HPV DNA. 
However, the mRNA-based test was negative in 35.9% of the women with CIN2+ in our 
study. Whether they represent CIN2+ lesions associated with regressing lesions or not, will be 
impossible to confirm since Norwegian women with CIN2+ lesions are routinely treated. It is 
not clear whether the increased specificity of the PreTect HPV-Proofer for detection of 
cervical neoplasia is driven truly by detecting transcripts or by detecting a more limited range 
of HPV types. DNA and mRNA testing may be applied together, to take advantage of the 
higher sensitivity and specificity of these respective tests. In such situations mRNA testing 
may act as a biomarker for progression of disease, but further data are needed to consolidate 
this. Only large follow-up studies of women with incident HPV infection can confirm whether 
mRNA testing is a marker to identify women at risk for progression of cervical neoplasia. 
 
 
 52 
PAPER IV 
In Paper IV we present the association of different HPV genotypes and presence of multiple 
HPV infections with severity of the cervical lesion in a cross sectional study. 
 
In cross-sectional studies exposure and outcome is measured simultaneously and the 
association between exposure and outcome cannot be confirmed. In spite of the cross-
sectional design, our results on the distribution of HPV genotypes according to severity of 
cervical neoplasia may help us gain insight into the oncogenic potential of the different HPV 
genotypes. 
 
Infection with HPV16 and HPV33 were associated with higher prevalence of CIN3+. The 
importance of HPV16 in development of high-grade cervical lesions has been documented in 
several other studies.139-141  
 
In our study, HPV18 was not associated with severity of cervical neoplasia. The lack of 
association may be explained by the limited statistical power in our study. HVP18 has shown 
to be more closely related to ACIS and adenocarcinoma than CIN.56 Of the included women 
in our study, only three percent were diagnosed with ACIS and two percent with invasive 
carcinoma, which may to some extent, explain our results regarding HPV18. Prior studies 
have also reported that the risk posed by HPV33 to induce CIN3 seemed higher than that of 
HPV18 and 45.139, 142 
 
Our study included all cases of CIN2+ during a two year period from a large source 
population. Still, we had limited statistical power to distinguish between effects of uncommon 
HPV genotypes; hence type 2 errors may have occurred. Our categorisation of HPV 
genotypes in the estimation of odds ratios was therefore determined by the prevalence of HPV 
genotypes in our study sample and also by the associations with CIN3+ observed in the data 
analyses when we studied each HPV genotype separately. In studies of HPV genotype 
specific risk of cervical neoplasia, there has been a lack of uniform reference category, 
making comparison between studies difficult 
 
It is still unclear whether multiple HPV infections with certain HPV genotypes will exert a 
synergistic effect on malignant transformation, or if cervical neoplasia can arise at multiple 
sites in the cervix. In our study, multiple HPV infections were detected in more than half of 
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the included women with CIN2+. Our results do not support an association of multiple 
infections with increased severity of cervical neoplasia, which is in agreement with other 
cross sectional studies.15, 44, 45, 48 Results from the Guanacaste Cohort Study, however, suggest 
that multiple infections may increase the risk of high-grade lesions and cervical carcinoma.46 
That study has the advantage of being prospective.  
 
Our study suggests differential risk of cervical neoplasia according to HPV genotype. 
Knowledge of HPV genotype specific prognosis may be essential to identify women at high-
risk of pre-cancerous cervical lesions, and important to better understand disease progression 
from CIN2 to invasive carcinoma. With such knowledge, HPV genotyping may be an 
important tool in cervical screening programmes. 
 
Based on the distribution of HPV genotypes in our study, vaccines against HPV16/18 have 
the potential to prevent at least 34.7 percent of CIN2+ lesions. If HPV16/18 are causal also in 
the presence of other high-risk HPV genotypes, the preventative potential may be 58.0 percent 
or higher, if reported cross-protection against other high-risk HPV genotypes are taken into 
account. 
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IMPLICATION OF FINDINGS AND SUGGESTIONS FOR FUTURE 
RESEARCH 
We found that cervical laser conisation and loop electrosurgical excision procedures are 
associated with increased risk of preterm delivery, low birth weight and pPROM in 
subsequent pregnancies. The risk of preterm delivery was most pronounced in the early 
gestational age groups in which the clinical significance is highest. About one-third of the 
women diagnosed with CIN2+ in Norway are younger than 29 years. The mean maternal age 
in primiparous is increasing and was 28 years in Norway in 2007.133, 143 Hence, a large 
proportion of the women treated with cervical cone excision have not yet given birth to their 
first child. Our results underscore the need for a careful clinical approach to women with 
previous cervical conisation when they become pregnant. Our study encourages research 
aimed at identification of women at true risk of cervical carcinoma since today’s 
overtreatment of all women with CIN2+ has side-effects.  
 
We have illustrated a potential effect of an HPV16/18 vaccination programme on prevention 
of preterm deliveries. Our estimations suggest that an HPV 16/18 vaccination programme for 
prevention of cervical cancer also would have preventive effect on preterm delivery through 
reducing the need for cervical cone excisions. This may have implications for cost 
effectiveness evaluations and policy making with regards to the introduction of prophylactic 
HPV vaccination programmes. Future research may give more accurate values to the factors 
that influence the number of preterm deliveries that may be prevented by HPV16/18 
vaccination. 
 
Since few precancerous cervical lesions actually progress to cervical carcinoma, there is 
reason to improve identification of women at risk for such progression, and thereby prevent 
unnecessary cervical cone excisions. It has been suggested that detection of oncogene activity 
through the detection of HPV mRNA transcripts rather than the presence of HPV DNA, may 
be a better indicator to identify women at risk of developing high-grade cervical lesions and 
cervical cancer. Our results showed that the concordance between HPV DNA testing and 
HPV mRNA testing was poor, and the mRNA-based test was the least sensitive test with 
regards to the detection of HPV. However, the mRNA-based test was the only test method 
that correlated with histology grade. DNA and mRNA testing may be applied together to take 
advantage of the higher sensitivity and specificity of these respective tests. In such a situation, 
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mRNA testing may act as a biomarker for progression of disease, but further data is needed to 
consolidate this. Future studies should focus on developing screening tools that have higher 
specificity for developing cervical carcinoma. This to help distinguish the women with high-
risk precursor lesions that will progress to invasive carcinoma from the vast majority of 
precursor lesions that spontaneously regress.  
 
 
We have performed a large Norwegian study of HPV genotype distribution in women with 
CIN2+. Our study provides a basis for future trend analyses of HPV distribution in Norway. 
Our results suggest that HPV16 and HPV33 increase the risk of CIN3+ compared to other 
high-risk HPV genotypes. However, the proportion of CIN3+ attributable to HPV16 is much 
higher than for HPV33, due to the much higher prevalence of HPV16. Our results do not 
support an association of multiple infections with increased severity of cervical neoplasia. 
Future studies should involve follow-up studies of a large number of women with incident 
HPV infection to give reliable estimates of each genotype’s specific prognosis. Knowledge of 
the natural history of each HPV genotype may be helpful to identify women with cervical 
precursor lesions that will spontaneously regress. Hence, unnecessary cervical cone excisions 
may be avoided and thereby preterm deliveries attributable to cervical cone excision.   
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In the present study we investigated the cross-sectional positivity for DNA and E6/E7 mRNA from high-risk
human papillomavirus (HPV) types in 643 women with high-grade cervical neoplasia (135 cases of cervical
intraepithelial neoplasia grade 2 [CIN2], 495 cases of CIN3/adenocarcinoma in situ [ACIS], and 13 cases of
invasive carcinoma) and in 736 women with normal cytology by using the Amplicor and PreTect HPV-Proofer
assays. In addition, genotyping was performed using Linear Array for women with normal cytology and a
positive HPV test and in all women with histologically conﬁrmed CIN2. In women with normal cytology, 8.3%
(61/736) were Amplicor positive and 3.3% (24/736) were PreTect HPV-Proofer positive (P< 0.001). Concordant
results between the Amplicor and PreTect HPV-Proofer tests were present in 90.3% (665/736). In women with
CIN2 lesions 96.4% (620/643) were positive by Amplicor, 98.4% (633/643) by linear array, and 64.1%
(412/643) by PreTect HPV-Proofer. Concordant results for the three HPV assays were present in 63.8%. The
genotype proﬁle detected by linear array and PreTect HPV-Proofer showed substantial agreement for HPV
types 16, 18, 33, and 45. HPV type 16 and/or 18 was detected in 58.8% (378/643) of the women with high-grade
neoplasia. Detection of E6/E7 mRNA by PreTect HPV-Proofer increased with severity of the cervical lesion.
Detection of HPV DNA, however, was not associated with histology grade. In conclusion, the detection of HPV
varied according to the assay used, and the concordance between the tests was poor. Our results indicate that
mRNA testing may be a biomarker for progression of cervical neoplasia, but the optimal genotype mix remains
to be determined.
Infection with human papillomavirus (HPV) is considered
the cause of the vast majority of premalignant and malignant
epithelial lesions of the cervix (8, 21, 29, 31). However, most
HPV infections are asymptomatic and transient, and more
than 90% of new infections will resolve within 2 years (19).
Progression to carcinoma is associated with a persistent infec-
tion with high-risk (HR) HPV types, integration of the HPV
genome into the host chromosomes, and upregulation of E6
and E7 oncogenes, which can lead to abrogation of normal cell
cycling events and tumor suppressor activity (7, 30, 31).
Large, randomized clinical trials have shown that HPV DNA
testing has a higher sensitivity but lower speciﬁcity than cytol-
ogy for detecting high-grade cervical lesions in primary screen-
ing (2, 5, 6, 12, 23, 24). As most HPV infections are transient,
HPV DNA testing could result in follow-up of women with
clinically insigniﬁcant infection, resulting in increased costs
and patient anxiety. This is why an informed approach to HPV
testing is imperative, with clinical contexts and reasons for
testing clearly deﬁned and justiﬁed, respectively.
Most commercially available HPV tests detect the presence
of HPV DNA; however, it is possible to detect HPV mRNA
transcripts coding for E6/E7 and thereby the presence of on-
cogene activity. A nucleic acid sequence-based ampliﬁcation
method detecting E6/E7 transcripts from the ﬁve most com-
mon HR HPV types in cervical carcinoma (types 16, 18, 31, 33
and 45) is commercially available from two companies (the
PreTect HPV-Proofer [Norchip AS, Klokkarstua, Norway] and
the NucliSens EasyQ [bioMerieux S.A., France]). The prevail-
ing consensus is that upregulated expression of E6/E7 is nec-
essary for the initiation and progression of cervical neoplasia.
Detection of HPV oncogene activity through the detection of
mRNA transcripts may therefore be a better indicator of HPV
infection associated with increased risk of progression to neo-
plasia than detection of HPV DNA (14, 17, 18).
The aims of our study were to investigate the cross-sectional
positivity of HR HPV DNA and E6/E7 mRNA expression in
women with and without cervical neoplasia by using two com-
mercial assays. A third broad-spectrum commercial genotyping
* Corresponding author. Mailing address: Department of Obstetrics
and Gynecology, Akershus University Hospital, Mailbox 24, 1478 Lø-
renskog, Norway. Phone: (47) 90655041. Fax: (47) 22935426. E-mail:
ameli.trope@me.com.
† Ameli Trope and Katrine Sjøborg contributed equally to this work.
 Published ahead of print on 17 June 2009.
2458
assay was included so that type-speciﬁc analysis could be per-
formed (on women with high-grade disease and on HPV-pos-
itive women with normal cytology). We also wanted to study
the association between testing positive by the different meth-
ods and the severity of the cervical lesion.
MATERIALS AND METHODS
Study population. Women were recruited from four hospitals and nine gyne-
cologists in private practice in Health Region East, Norway. Enrollment took
place from 1 January 2005 to 31 December 2006. Included in the study were (i)
764 women 30 years or older attending routinely administered clinical services
and with normal Pap smear cytology, normal cytological results from the pre-
ceding 2 years, and no previous history of treatment for cervical neoplasia and
(ii) 655 women (no age criterion imposed) with histologically conﬁrmed cervical
intraepithelial neoplasia grade 2 or 3 (CIN2), adenocarcinoma in situ (ACIS),
or invasive carcinoma. A total of 623 of these patients were treated with coniza-
tion. The median age among women with normal cytology was 51 years (range,
31 to 82 years), and it was 37 years (range, 17 to 76 years) for women with
CIN2.
The Pap smears were evaluated without knowledge of the HPV results by
different, experienced cytotechnicians at the Department of Pathology, Akershus
University Hospital. The smears were classiﬁed according to the criteria of the
Bethesda Classiﬁcation 2001 (26).
The histological analyses were performed on colposcopically directed biopsies
and/or cone specimens. All specimens were reevaluated blindly by one experi-
enced pathologist (A. K. Lie) and diagnosed according to the WHO classiﬁcation
(1). The specimen with the most severe lesion was chosen for analysis. Histology
revealed CIN2 in 21.0% (135/643), CIN3 in 73.7% (474/643), ACIS in 1.6%
(10/643), ACIS together with CIN2/3 in 1.7% (11/643), and invasive carcinoma in
2.0% (13/643) of the cases.
Collection of specimens for HPV testing. Cervical specimens were collected
with a Cytobrush Plus (Medscan Medical AB, Sweden). For the normal cytolog-
ical group a conventional Pap smear was taken ﬁrst and the brush was transferred
to a PreServ Cyt vial (Cytyc Corporation) for HPV testing. For the CIN2
group, samples were transferred directly to the PreServ Cyt medium at the time
of conization or at the time of biopsy within 2 months before conization. Cells
were stored in PreServ Cyt medium for up to 21 days at room temperature or at
4°C before HPV testing.
Total nucleic acid extraction. To allow one extraction for both mRNA and
DNA, the manual DNA extraction protocol (AmpliLute; Roche/Qiagen) sup-
plied with the Amplicor HPV test was replaced by the semiautomatic NucliSense
miniMag (bioMerieux) or automatic easyMag (bioMerieux) total nucleic acid
extraction protocol recommended by the PreTect HPV-Proofer test manufac-
turer. Brieﬂy, 5 ml of each cell sample in PreServ Cyt medium was pelleted by
centrifugation. In cases with visible blood, only 3 ml of the cell sample was used,
and in cases with few visible cells 10 ml of the cell sample was used. For the
miniMag procedure, 1 ml of lysis solution and 100 l of elution buffer were used,
and for the easyMag procedure 2 ml of lysis solution and 55 l elution buffer
were used. Isolated nucleic acid was kept cold and analyzed within 4 hours
following extraction or stored at 80°C until analysis.
Validation of the nucleic acid extraction procedure. To compare the perfor-
mance of easyMag extraction with AmpliLute extraction, 66 samples with high-
grade lesions were extracted in parallel by both methods. The DNA concentra-
tions in the extracts were determined using an in-house real-time beta-globin
PCR for absolute quantiﬁcation, using a dilution of human DNA with known
concentrations as a standard (data not shown). Undiluted and diluted extracts
were compared, as undiluted AmpliLute extracts were replaced by 1:10-diluted
easyMag extracts in the modiﬁed Amplicor test.
HPV DNA testing. The Amplicor HPV test (Roche Diagnostics, Switzerland)
detects the following HPV DNA genotypes: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56,
58, 59, and 68. The Amplicor test does not include genotyping, and a positive
result of the test is interpreted as the presence of one or more of the above
genotypes. As the AmpliLute manual extraction protocol was replaced by the
automatic extraction protocol described above using a larger input of sample (5
ml versus 250 l), 5 l total nucleic acid was diluted with 45 l PCR-grade water
instead of using 50 l undiluted Amplilute-extracted DNA in each PCR mixture.
All other steps in the analyses were performed according to the manufacturer’s
recommendations.
HPV DNA genotyping. HPV DNA genotyping was performed with the Linear
Array HPV assay (Roche Diagnostics, Switzerland) in women with normal cy-
tology and positive HPV test and in all women with histologically conﬁrmed
CIN2. This assay detects 37 different genotypes, including HR, probably HR,
low risk, and HPV types not yet classiﬁed (Table 1) (21). This was done retro-
spectively using the same extracts used for the Amplicor HPV test and PreTect
HPV-Proofer test. As for the Amplicor test the input for the PCR was 5 l
extract added to 45 l PCR-grade water. All other steps including analysis were
as recommended by the manufacturer.
HPV mRNA testing. The PreTect HPV-Proofer (Norchip, Norway) detects
HPV 16, 18, 31, 33, and 45 E6/E7 full-length mRNA transcripts. Brieﬂy, 5 l
undiluted isolated nucleic acid was analyzed according to the manufacturer’s
instructions using the Lambda FL 600 ﬂuorescence reader (Bio-Tek Instruments,
Inc.) and the PreTect analysis software (Norchip; Norway). Samples that were
HPV mRNA negative, internal control negative, or internal control indetermi-
nate (signal between 1.4 and 1.7), as well as samples that were HPV indetermi-
nate, were reextracted and reanalyzed using up to 10 ml PreServ Cyt sample as
recommended by the manufacturer (PreTect HPV-Proofer user guide version
1105 720001 and earlier versions; Norchip). Samples that tested indeterminate
twice were considered negative if the internal control was positive.
Statistical analyses. We compared the percentages of test positives according
to the assay used. Statistical analyses were performed using two-by-two contin-
gency tables with two-sided P values calculated with a Pearson chi-square test.
Fisher’s exact test and McNemar’s test were used for comparisons of paired
proportions. P values of 0.05 were considered statistically signiﬁcant. We also
calculated percent agreement between the different HPV assays, and values for
Cohen’s  statistic were used as indicators of concordance;  values of 0.20
indicated poor agreement, 0.21 to 0.40 fair agreement, 0.41 to 0.60 moderate
agreement, 0.61 to 0.80 substantial agreement, and 0.80 indicated nearly per-
fect agreement. Kappa values were calculated for agreement between assays on
detection of HPV 16, 18, 31, 33, and 45. Data analyses were performed by using
SPSS software (version 16.0). The relative sensitivity and speciﬁcity were calcu-
lated based on valid test results on 736 women with histologically conﬁrmed
CIN2 and 643 women with normal cytology.
Ethics. The Regional Committee for Ethics in Medical Research, East Region,
Norway (676-04239), Norwegian Social and Health Directorate (05/163), and
Norwegian Data Inspectorate (07/00975-2/SVE) approved the study. Written
informed consent was obtained from all study participants.
RESULTS
Validation of nucleic acid extraction procedure. Based on
the beta-globin real-time PCR performed on 66 samples with
high-grade lesions, the mean DNA concentration in undiluted
AmpliLute extracts was found to be 25  30 ng/l (mean 
standard deviation). The mean DNA concentration in 1:10-
diluted easyMag extracts was found to be 10  9 ng/l. Sub-
sequent analysis of the same samples with the Amplicor test
revealed 100% agreement regarding beta-globin gene detec-
tion (66 out of 66 samples were beta-globin positive) and
86.4% (95% conﬁdence interval, 76.1 to 92.7) agreement re-
garding HPV detection (57 out of 66 samples revealing the
same result). A total of 38 HPV-positive samples were de-
tected combining both extractions. Five of these were only
positive when extracted using the AmpliLute procedure, and
four were only positive when extracted using the easyMag
procedure. In conclusion, the agreement regarding detection
of the internal control was 100% and for HPV DNA it was
substantial (Cohen’s , 0.74). Mean DNA concentrations used
as input to the Amplicor test were similar, but DNA concen-
TABLE 1. HPV genotypes detected with the Linear Array
Classiﬁcationa HPV genotypes detected
High risk .............................16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59
Probably high risk..............26, 53, 66, 68, 73, 82, IS39
Low risk ..............................6, 11, 40, 42, 54, 61, 70, 72, 81, CP 6108
Not yet classiﬁed................55, 62, 64, 67, 69, 71, 83, 84
a The classiﬁcations are based on IARC recommendations (21).
VOL. 47, 2009 PERFORMANCE OF HPV DNA AND mRNA TESTING STRATEGIES 2459
trations in the easyMag extracts appeared to be more uniform
than the AmpliLute extracts. Based on these results we con-
cluded that the total nucleic acid automatic extraction method
could replace the more laborious manual AmpliLute extrac-
tion method.
HPV detection in women with normal cytology. In women
with normal cytology, 3.7% (28/764) of the cases were excluded
because both the internal control for DNA and/or RNA quality
and HPV were negative, leaving 736 with valid test results. A
total of 10.6% (78/736) tested positive for HR HPV (DNA
and/or mRNA). The Amplicor test was positive in 8.3% (61/
736) and the PreTect HPV-Proofer test was positive in 3.3%
(24/736) (Table 2). Concordant results between Amplicor and
PreTect HPV-Proofer were found in 90.3% (665/736). The
HPV-positive cases (n 	 78) were genotyped using Linear
Array, and 47 cases tested positive (60%). HPV was more
frequently detected using the Amplicor test or Linear Array
than with PreTect HPV-Proofer (Pearson chi-square test, P 
0.001) (Table 2). By Linear Array multiple infections with two
or more genotypes were detected in 1.4% (10/736) of all
women and in 12.8% (10/78) of women with positive samples,
but by PreTect HPV-Proofer no women were determined to
have multiple infections.
HPV detection in women with high-grade cervical neoplasia.
In women with CIN2, 1.8% (12/655) of the cases were ex-
cluded because the internal control for DNA and/or RNA
quality and HPV were negative, leaving 643 with valid test
results. A total of 97.0% (624/643) tested positive for HR HPV
(HPV DNA and/or HPV mRNA). Amplicor was positive in
96.4% (620/643), Linear Array was positive in 98.4% (633/
643), and PreTect HPV-Proofer was positive in 64.1% (412/
643) (Table 3). In women with CIN2 HPV was detected in
99.4% (639/643) when all HPV types detected by linear array
were considered. Agreement between Amplicor and PreTect
HPV-Proofer was found in 66.7% (429/643) (Table 3) and
between Linear Array and PreTect HPV-Proofer in 64.1% of
the samples (412/643) (Table 3). Concordant results for the
three HPV assays were present in 63.8% (410/643).
In total, Linear Array detected the presence of 34 different
HPV genotypes in women with CIN2, and the distribution of
the HR HPV genotypes is shown in Fig. 1. HPV 16 was the
most common HPV type, detected in 51.3% (330/643) of the
women, followed by HPV 31, 33, 52, 18, 51, 58, and 45. HPV
16 and/or 18 was detected in 58.0% (373/643). Probable HR
HPV genotypes were detected in 13.5% (87/643), low-risk
HPV genotypes in 18.0% (116/643), and genotypes that have
not yet been classiﬁed in 13.2% (85/643) of the women. Linear
Array detected multiple infections in 52.6% of the cases (338/
643). HPV 6/11 was detected in 2.0% (13/643), together with
other HPV types in most of the cases (1.7% [11/643]).
The distribution of HPV genotypes detected by the PreTect
HPV-Proofer is shown in Table 4. HPV 16 was the most
prevalent genotype, found in 42.3% (272/643) of the women,
followed by HPV 33 (13.2%), HPV 45 (6.1%), HPV 18 (5.3%),
and HPV 31 (2.3%). HPV 16 and/or 18 were detected in 47.1%
(303/643) of the women. Multiple infections with two or more
genotypes were detected in 5% (33/643) of the specimens by
PreTect HPV-Proofer. Of the 33 specimens with multiple in-
fections detected by HPV-Proofer, Linear Array results
showed at least one of the same genotypes.
For women with CIN2 the HR HPV genotype proﬁle
detected by Linear Array compared to PreTect HPV-Proofer
is shown in Table 4. Agreement between the two tests was poor
to moderate for HPV 31 ( value, 0.18) and substantial for
HPV 18, 16, 33, and 45 ( values, 0.68 to 0.81). In women who
were Amplicor positive and PreTect HPV-Proofer negative
(n 	 211), genotyping with Linear Array revealed an HR HPV
genotype not included in the mRNA test in 41.2% (87/211).
There was 96.7% concordance between Amplicor and Linear
Array test results.
HPV test results according to severity of cervical disease.
Amplicor was positive in 95.6% cases of CIN2 (129/135), in
97.0% cases of CIN3/ACIS (480/495), and in 84.6% of cases of
invasive carcinoma cases (11/13) (Table 5). Two invasive car-
cinomas were Amplicor negative. mRNA testing revealed on-
cogene expression from HPV 45 in one of these cases, and
results were negative in the other. PreTect HPV-Proofer was
positive in 50.4% of the women with CIN2 (68/135), in 67.5%
with CIN3/ACIS (334/495), and in 76.9% of the women with
invasive carcinomas (10/13). Three invasive carcinomas tested
negative with PreTect HPV-Proofer, and genotyping with Lin-
ear Array revealed HPV 11, 33, 81, and 56. The HPV11-
positive invasive carcinoma was classiﬁed as a condylomatous
type of squamous cell carcinoma, a newly described type in the
WHO 2004 classiﬁcation. The mRNA test was signiﬁcantly
more often positive in the CIN3 lesions compared to CIN2
lesions (Pearson chi-square test, P  0.0001). Detection of
HPV DNA, however, was not associated with histology grade.
The relative cross-sectional sensitivity and speciﬁcity were calcu-
TABLE 3. Outcome of HPV testing by PreTect HPV-Proofer,
Amplicor, and Linear Array in the CIN2 group
Comparison test and
result
Result with PreTect HPV-Proofer
% Negative (n) % Positive (n) Total % (n)
Amplicor
Negative 3.1 (20) 0.5 (3) 3.6 (23)
Positive 32.8 (211) 63.6 (409) 96.4 (620)
Total 35.9 (231) 64.1 (412) 100.0 (643)
Linear Array
Negative 0.8 (5) 0.8 (5) 1.6 (10)
Positive 35.1 (226) 63.3 (407) 98.4 (633)
Total 35.9 (231) 64.1 (412) 100.0 (643)
TABLE 2. Outcomes of HPV testing with PreTect HPV-Proofer,
Amplicor, and Linear Array in the normal cytology group
Comparison test and
result
Result with PreTect HPV-Proofer
% Negative (n) % Positive (n) Total % (n)
Amplicor
Negative 89.4 (658) 2.3 (17) 91.7 (675)
Positive 7.3 (54) 1.0 (7) 8.3 (61)
Total 96.7 (712) 3.3 (24) 100.0 (736)
Linear Array
Not tested 89.4 (658) 0 (0) 89.4 (658)
Negative 2.0 (15) 2.2 (16) 4.2 (31)
Positive 5.3 (39) 1.1 (8) 6.4 (47)
Total 96.7 (712) 3.3 (24) 100.0 (736)
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lated (Table 6) and revealed the highest sensitivity for HPV DNA
testing and the highest speciﬁcity for HPV mRNA testing.
DISCUSSION
The aims of our study were to compare relatively new com-
mercially available assays for detection of HPV in Norwegian
women with and without high-grade cervical neoplasia as the
baseline for longitudinal analyses. HR HPV was detected in
10.6% of women above the age of 30 with normal cytology and
8.3% tested positive with Amplicor, which is in agreement with
other European studies using HC II or consensus PCR (3, 9,
10, 17). Among the specimens from women with normal cytol-
ogy, a signiﬁcantly higher number were positive by Amplicor
than by PreTect HPV-Proofer (P  0.001). The reason for this
may be that more genotypes are included in the DNA test (13
versus 5 genotypes) and/or that the chemistry behind the
mRNA test renders it more speciﬁc for the detection of clin-
ically signiﬁcant infection. Those with HPV E6/E7 mRNA-
negative detection in HPV DNA-positive samples can be in-
terpreted as HPV carriers without active viral transcription.
However, it may be that transcriptional activity occurs but at
levels insufﬁcient for PreTect HPV-Proofer detection. Surpris-
ingly, with PreTect HPV-Proofer samples tested positive in
2.3% of the Amplicor-negative cases. This could be have been
caused by a false-positive mRNA test (oncogene expression
FIG. 1. Distribution of genotypes in positive tests among 643 women with CIN2 detected by linear array. *, probably high-risk HPV genotype
(25, IS 39, 53,66, 68, 73, and 82); **, HPV low-risk genotype (6, 11, 40, 42, 54, 61, 70, 72, 81, and CP 6108) or unclassiﬁed genotype (55, 62, 64,
67, 69, 71, 83, and 84).
TABLE 4. Distribution of HPV genotypes detected by PreTect HPV-Proofer and Linear Array in the CIN2 group (n 	 643)
HPV
Genotype(s)
PreTect HPV-Proofer Linear Array % with positive results
in both testsa P value  value% Positive (n) % Negative (n) % Positive (n) % Negative (n)
16 42.3 (272) 57.7 (371) 51.3 (330) 48.7 (313) 79.7 (267) 0.001 0.79
18 5.3 (34) 94.7 (609) 10.9 (70) 89.1 (573) 48.6 (34) 0.001 0.63
31 2.3 (15) 97.7 (628) 16.3 (105) 83.7 (538) 12.1 (13) 0.001 0.18
33 13.2 (85) 86.8 (558) 15.2 (98) 84.8 (545) 71.0 (76) 0.001 0.80
45 6.1 (39) 93.9 (604) 6.8 (44) 93.2 (599) 69.4 (34) 0.001 0.81
16/18 47.1 (303) 52.9 (340) 58.0 (373) 42.0 (270) 78.8 (298) 0.001 0.75
a Percent (number) of HPV-positive women who tested positive on both PreTect HPV-Proofer and Linear Array.
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not associated with cervical neoplasia), lack of speciﬁcity of
PreTect HPV-Proofer, or false-negative DNA tests due to a
breakpoint in the L1 region during HPV integration. We in-
tend to follow these women with repeat cytology and HPV
testing after 12 months; if HPV infection is persistent and/or
cytology is positive by colposcopy, biopsy will be performed.
In our study PreTect HPV-Proofer was positive in 3.3% of
the women with normal cytology, which is higher than reported
from another, larger cross-sectional Norwegian study where
PreTect HPV-Proofer tested positive in 1.7% (68/3970) of
women above the age of 30 with normal cytology (17). Castle
et al. tested women in a routine screening program with the
Aptima HPV assay (which can detect E6/E7 mRNA from 14
carcinogenic HPV types) and found that 8% (10/125) of
women with normal cytology tested positive (4). It could be
argued therefore (notwithstanding the analytical sensitivities of
the two mRNA assays) that the smaller type range of the
PreTect HPV-Proofer has contributed to the lower detection
rate.
Due to the lower detection of HPV mRNA in women with
normal cytology, it may constitute a better ﬁrst-line screen
compared to HPV DNA testing, provided the sensitivity for
signiﬁcant disease is not compromised and clinically signiﬁcant
infections are not missed. Longitudinal follow-up (including
that associated with mRNA-negative/DNA-positive women)
from this study should elucidate the prospective performance
of the tests.
HR HPV was detected in 97.0% of women with histologi-
cally conﬁrmed CIN2. A signiﬁcantly higher number of
women with CIN2 were HPV DNA positive rather than
HPV mRNA positive. Concordant results for the three HPV
tests were found in 63.8%. There are several explanations for
the different outcomes of the tests. The different assays are not
uniform with regard to the analytical sensitivity, use of tem-
plate, and the spectrum of detectable genotypes. PreTect
HPV-Proofer detects transcripts and oncogene activity from 5
out of the 13 HR HPV types included in the Amplicor test. The
Linear Array, which detects 37 different genotypes, has lower
analytical sensitivity than the Amplicor test. The concordance
between Amplicor and the Linear Array in the CIN2 group
was 96.7%, which is almost the same as in the study of Steven
et al. (97.8%) (27).
We detected an HR HPV genotype not included in the
mRNA test in 41.2% of the women with CIN2 (i.e., positive
Amplicor and negative PreTect HPV-Proofer). HPV DNA
testing will not discriminate between active and latent or tran-
sient infections, while mRNA testing may be more likely to. It
is estimated that only 12 to 31% of CIN3 lesions will progress
to invasive carcinomas if they are left untreated (15, 16, 22), so
it could be that the HPV mRNA-negative/DNA-positive
CIN2 cases were those infections associated with regressing
lesions. However, this will be impossible to conﬁrm, since Nor-
wegian women with CIN2 lesions are routinely treated with
conization.
In our study 96.4% of women with CIN2 tested positive with
Amplicor, which is in accordance with the large POBASCAM
and ARTISTIC trials, in which HPV DNA testing was per-
formed with PCR or hybrid capture 2 (2, 9). The Amplicor test
was negative in 23 women with CIN2, and among these, 3
patients tested positive with PreTect HPV-Proofer. As dis-
cussed earlier, the reason for this may be false-negative DNA
tests associated with viral integration.
There is a lack of data on mRNA testing in clinical contexts.
Cross-sectional Norwegian studies have shown that mRNA
transcripts from HPV types 16, 18, 31, 33, or 45 can be de-
tected in 77% of women with histologically veriﬁed CIN2
and in 89% of invasive squamous cell carcinomas, compared to
94.5% and 92%, respectively, by HPV DNA testing (11, 14,
17). These studies support our results that HPV detection in
preinvasive lesions will differ depending on whether you use
mRNA methods with fewer genotypes or HPV DNA detection
methods with a broad spectrum of genotypes. The Aptima
HPV assay, a Gen-Probe test detecting E6/E7 mRNA for 14
carcinogenic HPV types, showed a prevalence of 92.4% in
women with CIN2 (4). Adding extra (probably) oncogenic
HPV types in mRNA HPV tests may negatively inﬂuence the
speciﬁcity of the test for high-grade lesions (13, 25). The per-
formance of the PreTect HPV-Proofer assay is clearly inﬂu-
enced by the choice and number of genotypes included in the
assay. It remains to be documented whether mRNA assays
need to be intrinsically quantitative to be effective. In deter-
mining the optimal genotype mix for an mRNA test, indeed
any HPV test is a contentious area. There will have to be a
TABLE 5. Relationship between morphology and HPV testing
Morphology (n)
PreTect HPV-Proofer Amplicor P value,
Proofer vs
Amplicor
Linear Array P value,
Proofer vs
Linear Array% Positive (n) % Negative (n) % Positive (n) % Negative (n) % Positive (n) % Negative (n)
Normala (736) 3.3 (24) 96.7 (712) 8.3 (61) 91.7 (675) 0.0001 60.3 (47) 39.7 (31) 0.001
CIN2 (135) 50.4 (68) 49.6 (67) 95.6 (129) 4.4 (6) 0.091 98.5 (133) 1.5 (2) 0.992
CIN3/ACIS (495) 67.5 (334) 32.5 (161) 97 (480) 3 (15) 0.0001 98.8 (489) 1.2 (6) 0.072
Carcinoma (13) 76.9 (10) 23.1 (3) 84.6 (11) 15.4 (2) 0.326 84.6 (11) 15.4 (2) 0.4
CIN2 (643) 64.1 (412) 35.9 (231) 96.4 (620) 3.6 (23) 0.0001 98.4 (633) 1.6 (10) 0.35
a For women with normal cytology, genotyping with Linear Array was performed only in cases with a positive HPV test (positive by Amplicor and/or PreTect
HPV-Proofer).
TABLE 6. Sensitivities and speciﬁcities for the three tests
Test % Sensitivitya % Speciﬁcityb
Amplicor 96.4 91.7
Proofer 64.1 96.7
Linear Array 98.4 NAc
a Based on 643 women with histologically conﬁrmed CIN2.
b Based on 736 women with normal cytology.
c NA, not available. Speciﬁcity could not be measured using the Linear Array
as only some (n	 78 HPV positive) of the 736 women with normal cytology were
tested via this technique.
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compromise between including more rare HPV types to max-
imize sensitivity and detecting large numbers of what could be
clinically irrelevant infections. Deﬁning the appropriate ana-
lytical sensitivity for clinical utility is equally challenging.
According to the known prevalence of HPV types in invasive
cervical carcinomas, more than 80% of the potential cases can
be detected by the PreTect HPV-Proofer assay. The IARC
pooled analysis of 3,085 invasive cervical carcinomas revealed
that the ﬁve most common HPV genotypes were, in descend-
ing order of frequency, HPV 16, 18, 45, 31, and 33 (20). These
genotypes were detected in 82.9% of the cases, which corre-
sponds well with a Norwegian study of 204 women diagnosed
with squamous cell carcinomas (11). In that previous study the
ﬁve most common HPV genotypes were 16, 18, 31, 33, and 45.
DNA and mRNA testing may be employed together for
screening to take advantage of the higher sensitivity and spec-
iﬁcity, respectively, of the tests, and patients are then referred
for a biopsy if both tests are positive. If only HPV DNA is
positive, the patient may be retested for HPV DNA at a later
date and then referred for colposcopy if persistently positive.
mRNA testing alone for screening appears to be too insensi-
tive, at least for the currently evaluated PreTect HPV-Proofer
assay. Moreover, as HPV vaccination becomes more common
and the prevalence of HPV vaccine types is reduced, there will
be a requirement to reconsider/recalibrate HPV assays in line
with the shifting dynamics of HPV type-speciﬁc prevalence and
associated disease.
Accurate geographical data on HR HPV genotype distribu-
tions have implications not only for follow-up protocols in
cervical cancer screening programs but also for assessing the
expected impact of an HPV 16/18 vaccine program on CIN2.
In our study, 58.8% of the women with CIN2 tested positive
for HPV 16 and/or 18 as detected by either Linear Array or
PreTect HPV-Proofer. This result corresponds with a recent
meta-analysis which showed that HPV 16 and/or 18 was de-
tected in 52% of women with high-grade precursor lesions
(25a).
So far only one study has investigated the predictive values
of HPV DNA versus mRNA testing in triage (28). This study
revealed that PreTect HPV-Proofer has the highest speciﬁcity
and the lowest sensitivity, which seems to be in accordance
with our ﬁndings. At this stage we cannot calculate positive or
negative predictive values from our study, due to the absence
of histology results from the normal cytology group.
In conclusion, the detection of HPV varied according to the
assay used, and the concordance between the tests was low.
Our results indicate that mRNA testing may be a biomarker
for progression of cervical neoplasia, but further data are
needed to conﬁrm this. mRNA testing for the ﬁve HR HPV
types described may be a more speciﬁc approach and appro-
priate for risk evaluation. It is not clear whether the increased
speciﬁcity of mRNA testing via the PreTect HPV-Proofer is
driven by truly detecting transcripts or by detecting a more
limited range of HPV types. Consensus on the number and
types of genotypes that should be included in a diagnostic test
to achieve the best sensitivity and speciﬁcity has not been
reached and will likely evolve as interventions such as HPV
vaccination become more common.
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LIST OF ERRATA 
(Updated December 15, 2010) 
 
 
1. Page 6. The headline “Implications of findings and future research” was missing in 
“Table of contents” and is now included. 
 
2. Page 9. The word “now” was missing in line three in the second paragraph and is now 
included. 
 
3. Page 17. In line six in the second paragraph, “high-risk cervical neoplasia” is now 
replaced by “high-grade cervical neoplasia”  
 
4. Page 19. In line eight, the word “dived” is corrected to “divide”.    
I thank Rudi Henriksen for this correction. 
 
5. Page 28. In line one in the fourth paragraph, the word “Gradacil” is corrected to 
“Gardacil”. 
I thank Rudi Henriksen for this correction. 
 
6. Page 40. In line two in the third paragraph, the abbreviation “LCL” is now corrected to 
“CLC”. 
 
 
 
 
 

